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CHAPTER 1 
 
 
 
BACKGROUND AND OBJECTIVES 
 
Recent Advances in Drug Discovery and Development 
 Diseases and infections are diagnosed every year and the demand for 
reliable and effective therapies is ever-growing. Originally, drugs were discovered 
by identifying the active ingredient in traditional remedies, or by fortuitous 
discovery of an efficacious compound.[1]  Today, a more rigorous approach is 
taken to identify and understand key molecular components (i.e. therapeutic 
targets) of disease and infection.  In recent years, genomic and proteomic 
studies have identified a large number of disease markers, providing a myriad of 
potential therapeutic targets.[2-6]  These new targets have spurred the 
pharmaceutical industry to produce many more potential drug compounds in the 
hopes of improving and extending lives.  Despite advances in understanding 
biological systems, drug discovery and development is still a lengthy process 
with a low rate of novel therapeutic discovery.[7-9]  Much of this bottle-neck comes 
from the analytical evaluation of potential compounds.[9, 10]  New technologies are 
needed to minimize the attrition rate of lead compounds, especially in the areas 
of early drug disposition screening and evaluation. 
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Drug Discovery and Development Process 
In the pharmaceutical industry, drug discovery and development is the 
process by which drugs are discovered and designed for treating, curing, or 
preventing disease in human beings or animals.  In general, many steps are 
taken for the successful introduction of a drug to market (Figure 1).[9]  Simply, the 
process can be divided into two phases: 1) drug discovery and 2) drug 
development.  The discovery phase (1) involves the identification of drug 
candidates, typically by high-throughput screening assays of small molecule 
libraries against a target to identify compounds with strong binding affinities.  The 
compounds that achieve the acceptable criteria for a lead compound are then 
further optimized with the synthesis of many new structural analogs.  These 
analogs are also assayed to determine binding affinities to the target.  The best 
compounds are then examined under a wider set of parameters such as 
metabolic stability, bioavailability, safety, and efficacy.  The compounds that 
successfully exhibit the best profile will be promoted to the development phase 
(2). 
 In the development phase, steps are taken to evaluate the 
pharmacokinetic (PK) and pharmacodynamic (PD) effects of the lead compound.  
This can include collecting data on the therapeutic or toxicological response in a 
small animal model, as well as, preparing the compound for clinical trials through 
formulation, purity, and stability studies.  Once the lead compound fulfills all the 
necessary requirements, it enters into the clinical trials.  Several reviews are 
available that give greater detail of a compound’s path to market.[9, 11-13]   
 3
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Schematic diagram of the steps taken to successfully introduce a pharmaceutical compound to market. 
Adapted from Honing et al.[14] 
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Technological Trends in Pharma 
 The introduction of a new drug to market takes on average eight years or 
more and costs approximately $500 million to develop.[8]  A bulk of the time and 
money is spent on following lead compounds that all too often prove to be 
unsuccessful in clinical trials.  Rapidly identifying and validating potential drug 
therapies has become a major driving force in the pharmaceutical industry and 
has lead to new technological developments that can facilitate the rapid 
screening of promising lead compounds earlier in the drug discovery and 
development process. This strategy has created a technological paradigm of 
“more, faster, and cheaper.”  For example, small-molecule libraries have 
increased the number of novel compounds that can be synthesized (e.g. 
“more”).[15, 16] As a result, analytical techniques that can quickly screen for 
optimal lead compounds were developed such as multiplexed in vitro binding or 
enzymatic assays (e.g. “faster”).[17] Of even greater value were the technologies 
that were capable of making such evaluations by consuming less sample while at 
the same time providing increased sensitivity, such as micro-total analysis 
systems (e.g. “cheaper”).[18] 
Despite these advancements, there is still plenty of room to grow.  
Particularly, in the area of drug disposition where the cost and man-hours 
required to synthesize a radiolabeled drug compound significantly hinder 
throughput.  For this reason, imaging studies in small animal models are 
reserved for the more promising lead compounds in the much later development 
stage.  However, only 5-10% of the compounds that go into the development 
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stage actually ever make it to market.[7, 11]  The main reason that compounds fail 
is due to unacceptable ADME properties which are determined by the imaging 
studies.  Being able to see where a drug candidate is distributed in a whole-
animal helps to better assess the potential value of that compound.  To that end, 
better imaging technologies are needed that can provide “more, faster, cheaper” 
analyses early in the discovery phase, before the compound moves into the more 
costly drug development phase.   
 
Mass Spectrometry in Pharmaceutical Analyses 
Many scientific disciplines are involved in the discovery and development 
of new drugs, from medicinal chemistry, toxicology, pharmacology, and analytical 
chemistry.  These disciplines must work cooperatively to unravel the complex 
processes involved in disease and therapeutic intervention. In the case of 
analytical technologies, mass spectrometry (MS) has been widely used in many 
aspects of pharmaceutical research and development, from structural 
characterization of new chemical entities, metabolite identification, and 
pharmacokinetic studies.[14, 19]  This widespread use of mass spectrometry can 
be owed to its high sensitivity, molecular specificity, and rapid analysis times.  
Most of mass spectrometric analyses rely on separation techniques such as 
capillary electrophoresis, gas chromatography, and especially liquid 
chromatography (LC).   With the advent of electrospray ionization, LC 
separations gained popularity due to the robust interface with the mass analyzer, 
providing a relatively straightforward means of drug analysis.  Although valuable 
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information can be gained using LC-MS techniques, the spatial context of both 
the drug and metabolite compounds within the tissue is lost in these studies. 
 
Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry 
The ionization technique known today as matrix-assisted laser 
desorption/ionization (MALDI) was introduced by Karas and Hillenkamp in 
1985.[20]  This initial paper described the influence of laser wavelength on the 
desorption of various organic molecules. The authors noticed the increasing ion 
yields of non-absorbing amino acids and dipeptides in the presence of ultraviolet 
(UV) energy absorbing amino acids at much lower irradiance thresholds. The 
wavelength absorbing amino acids were hypothesized to serve as a low 
irradiance energy absorbing matrix that allowed for the ionization of intact non-
absorbing species. The authors realized the value of this observation and 
postulated the future application of the wavelength absorbing matrix molecules 
for the analysis of small organic molecules by laser desorption mass 
spectrometry and hence the term MALDI was coined.[21] 
 The breakthrough for large molecule analysis by laser desorption 
ionization arrived in 1988 with the work of Tanaka and colleagues and was 
awarded the 2002 Nobel Prize in Chemistry.[22]  Tanaka found that by using a 
mixture of ultra fine metal powder (e.g. cobalt) in glycerol as a matrix, a large 
protein or polymer could be ionized without fragmentation.  This ionization 
technique became known as “soft laser desorption” (SLD).   While MALDI was 
developed prior to SLD, it was not used to ionize proteins until after Tanaka's 
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work. Karas and Hillenkamp were able to ionize albumin (67 kDa protein) using 
nicotinic acid as a MALDI matrix.[23]  Further experiments identified derivatives of 
cinnamic acid to be relatively inexpensive, yet effective MALDI matrices.[24]  
Today, many researchers rely on the soft nature of MALDI MS for the molecular 
analysis of many endogenous and exogenous analytes from biological samples. 
 
MALDI 
 In MALDI MS analyses, the use of a low molecular weight organic 
compound that absorbs the laser energy, known as a matrix compound, is 
necessary to assist in the desorption and ionization process of non-volatile 
analytes.  Prior to analysis, the matrix compound is allowed to co-crystallize with 
analytes in a given sample, at a typical matrix to analyte ratio of 5000:1.  The 
most commonly used matrix compounds include 3,5-dimethoxy-4-
hydroxycinnamic acid (sinapinic acid, SA), α-cyano-4-hydroxycinnamic acid 
(CHCA), and 2,5-dihydroxybenzoic acid (DHB) (Figure 2).  The selection of a 
matrix compound can depend on the chemical properties of the analyte, sample 
conditions, and the wavelength of the laser.  Most commercially available 
instruments are equipped with the relatively inexpensive nitrogen laser (337 nm) 
or the more expensive solid-state Nd:YAG laser (355 nm).  While most 
instruments employ UV lasers, infrared (IR) lasers have been successfully used 
in MALDI MS applications.[25-27]  Absorption of the UV radiation from a laser pulse 
by the crystals subsequently causes matrix and analyte molecules to desorb from 
the sample surface. Gas-phase ionization occurs in the desorbed MALDI plume  
 8
 
 
  
 
 
Figure 2.  Structures of the common matrices used in MALDI MS analyses.  a) 3,5-dimethyoxy-4-hydroxycinnamic acid 
(sinapinic acid, SA), b) α-cyano-4-hydroxycinnamic acid (CHCA), and c) 2,5-dihydroxybenzoic acid (DHB). 
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to generate ions, predominantly singly protonated intact molecular ions [M+H]+ 
(Figure 3).   
 
Imaging MALDI 
 Extending the MALDI MS technology to map the location of analytes from 
an original sample is known as Imaging MALDI MS.  The procedure uses MALDI 
MS to systematically raster over a sample to produce ions at known x,y locations 
for downstream analysis.  Each mass spectrum at a specific coordinate becomes 
a pixel in a two-dimensional molecular map of the sample, with each pixel 
containing the analyte signals and associated relative abundances.  A molecular 
ion image of the sample is produced when an m/z value is selected and its 
intensity at specific locations is displayed (Figure 4). 
 The concept of using mass spectrometry to investigate the spatial 
arrangements of analytes dates back several decades and is termed imaging 
mass spectrometry (IMS).  Much of the early work in IMS was performed by 
secondary ion mass spectrometry (SIMS).  Early imaging SIMS experiments 
were performed to study the elemental compositions of inorganic metals and 
molecular distributions within samples.[28, 29]  Current applications of  SIMS 
technology has been limited to low mass analytes (<1000 Da) due to low ion 
yields and damage to the analyte during the ionization process.[31] 
With the introduction of MALDI in the mid- to late-1980s, a soft-ionization 
technique was established for the analysis of labile analytes.  The first imaging 
MALDI MS experiments were reported in 1997 by the Caprioli laboratory.  In this  
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Figure 3.  Cartoon depiction of the MALDI ionization process.  Matrix and analyte molecules are allowed to co-
crystallize on the target plate.  A laser pulse causes both molecules to desorb from the sample surface and 
subsequent protonation of the analyte by the matrix occurs in the gas-phase.  
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Figure 4.  Cartoon representation of the imaging MALDI MS experiment.  Adapted from Stoeckli et al.[30] 
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first report, imaging experiments were successfully demonstrated by the 
desorption of endogenous peptide and protein compounds directly from tissue 
sections, as well as, from tissue blots prepared on C-18 coated membranes.[32]  
Since then, imaging MALDI MS experiments have been successfully employed to 
desorb and detect drugs, lipids, peptides, and proteins directly from tissue 
samples.[25, 33-43] 
Imaging MALDI MS experiments can be performed with minimal 
preparative steps, with the most notable step being matrix application.  The area 
to be ablated must be uniformly covered in matrix, whether by a continuous 
coating or a droplet array, to produce high-quality and reproducible images.  
Practical aspects of tissue sample preparation, as well as, instrument parameters 
for an Imaging MALDI MS experiment are described in more detail in Chapter II 
or can be referenced elsewhere.[39, 44, 45]    
 
Instrumentation for MALDI Mass Spectrometry 
 Owing to the soft ionization of intact analyte species by MALDI, the 
ionization technique gained popularity for the analysis of a broad mass range of 
molecular ions.  The capability of the MALDI process to desorb and ionize 
versatile analyte species requires an equally accommodating mass analyzer. 
Therefore, MALDI is commonly coupled to time-of-flight (TOF) mass analyzers.  
TOF mass analyzers are relatively simple and are capable of analyzing ions 
ranging from a few Dalton (Da) to greater than 200 kDa. 
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 A MALDI-TOF mass spectrometer is composed of two regions: 1) an ion 
source where ions are produced and accelerated, and 2) a field-free drift tube 
terminates at the ion detector.  The two regions are maintained under vacuum, 
with pressures in the range of 10-7 to 10-8 Torr.  Following a laser pulse, all 
desorbed ions are accelerated into the mass analyzer by a homogeneous electric 
field of known strength, generally ± 20 kV.  From basic principles, it is understood 
that the potential energy of a charged particle in an electric field is related to its 
charge and to the strength of the electric field: 
UqEp ⋅=      (1) 
where pE  is the potential energy, q  is the charge of the particle, and U  is the 
electric potential or voltage.  
 
The acceleration caused by U results in ions of the same charge to have 
equivalent kinetic energies ( kE ): 
kp EE =      (2) 
The kinetic energy of a given mass is defined as: 
2
2
1 vmEk ⋅⋅=      (3) 
where m  is the mass and v  is the velocity.  
Based on equation (2), equations (1) and (3) can be combined: 
2
2
1 vmUq ⋅⋅=⋅     (4) 
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The velocity of an ion can be determined by measuring the flight time of an ion 
( TOFt ) down a flight tube of known length (d ): 
TOFt
dv =      (5) 
Equation (5) can now be substituted into equation (4): 
2
2 ⎟⎟⎠
⎞
⎜⎜⎝
⎛⋅=⋅
TOFt
dmUq     (6) 
and rearranged to solve for time of flight ( TOFt ): 
Uq
mdtTOF ⋅⋅⋅= 2     (7) 
Delayed extraction is the term used to describe the time-lag that occurs 
after the laser pulse, but before the accelerating potential is applied.  Since mass 
resolution and accuracy is dependent on the spatial homogeniety and energy 
distribution of the ions as they are accelerated into the TOF, delayed extraction is 
used to correct for initial energy differences and spatial heterogeneity that occurs 
in an expanding MALDI plume. Once the accelerating voltage is applied, the ions 
furthest from the voltage source will be accelerated more and the ions closest to 
the voltage source will be accelerated less.  When the delay time is properly 
adjusted, the ions will be spatially focused at the detector.  Given that the ion 
spends some time in the source of fixed length ( 0d ) under delayed extraction 
conditions, this time period ( st ) must also be considered for the total flight time, 
since the time-of-flight measurement is triggered by the laser pulse: 
Uq
mdts ⋅⋅⋅⋅= 22 0     (8) 
 15
Therefore, the total time-of-flight (T ) can be expressed as: 
Uq
mddttT sTOF ⋅⋅⋅+=+= 2)2( 0   (9) 
Since instrument dimensions and operating potentials are known, these variables 
can be replaced with a constant, k , in the equation: 
q
mkT ⋅=      (10) 
Consequently, equation (10) describes the flight time of an ion to be inversely 
proportional to its m/z (where the q  has been replaced by a z).  As a result, lower 
molecular weight ions will reach the detector in a shorter time than larger 
molecular weight ions.   More detailed descriptions of the MALDI-TOF 
instrumentation and delayed extraction conditions can be found in several 
reviews.[46-48] 
 
Advantages of MALDI Tandem Mass Spectrometry 
MALDI-TOF instrumentation has gained popularity for the analysis of 
complex biological samples for the detection of carbohydrates, lipids, peptides, 
proteins, and polynucleotides.[49-51]  The broad range of application can be owed 
to the high sensitivity, “limitless” mass range, and simplicity of spectral 
interpretation for the MALDI-TOF technique.  Typically, complex mixtures of 
analytes as low as a few femtomoles can be routinely detected and since the 
MALDI process produces predominately singly charged ions, the peaks can be 
interpreted without the need for deconvolution.  Despite these clear advantages, 
in the case of small molecule detection, MALDI-TOF MS analyses prove to be 
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disadvantageous due to the chemical noise from excess matrix molecules.  The 
matrix molecules (see Figure 2) can complicate the low mass region of interest, 
masking the presence of an analyte by ion suppression effects or isobaric peaks.  
For this reason, tandem mass spectrometry is often employed for small molecule 
analyses.   
Tandem mass spectrometry, or MS/MS analysis, requires an additional 
mass analyzer in the instrument design.  Mainstream MALDI MS/MS instruments 
include quadrupole ion traps (QIT), TOF-TOF, and quadrupole-TOF (QqTOF) 
analyzer configurations.  The advantage of a tandem mass spectrometer can be 
two-fold, selectivity (ultimately providing increased sensitivity) and structural 
identification.  The advantage of selectivity occurs in the first mass analyzer 
region, where customarily, a narrow mass window of ions centered on an analyte 
ion of interest is allowed to persist while ions falling outside that mass window 
are rejected. The ions that remain in the mass spectrometer (i.e. precursor ions) 
are then subjected to fragmentation by collision induced fragmentation (CID) with 
neutral gas molecules.  The fragment ions (i.e. product ions) are then detected 
and can be used to relate back to the structure of the precursor ion.  Therefore, 
the product ion pattern affords an added level of confidence by providing 
structural confirmation of the precursor ion.  Consequently, tandem mass 
spectrometry can resolve a matrix ion that is isobaric to the precursor ion, 
provided the matrix ion does not share an identical peak in the product spectra. 
Currently, the standard instrument for small molecule analysis by MALDI 
MS/MS is the QqTOF configuration.[52]  Briefly, the QqTOF is similar to a triple 
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quadrupole with the last quadrupole replaced by a TOF analyzer (described in 
previous section).  A detailed review of triple quadrupoles can be referenced for 
more information.[53]  A schematic representation of a MALDI-QqTOF instrument 
can be seen in Figure 5.  In the case of the QqTOF mass spectrometer, an 
additional radio frequency (RF) only quadrupole (Q0) is added to provide 
collisional cooling and focusing of the ions from the MALDI source.  Minimal 
extraction voltages (±10 V) are needed to accelerate the ions from the MALDI 
source into Q0.  During an MS/MS analysis, the second quadrupole (Q1) acts as 
a mass filter allowing ions within mass windows of ± 0.1-2.5 Da to continue on 
into the mass spectrometer.  The ions are then accelerated (20-200 eV) into the 
collision cell (Q2), where they undergo CID.  After leaving Q2, the product ions 
are reaccelerated in the orthogonal direction by a pulsed electric field (kHz) into 
the TOF analyzer for detection.  Ultimately, the advantage of a QqTOF over other 
MALDI MS/MS instruments is the high mass resolution (10,000) and very high 
mass accuracy (a few ppm). 
 
Direct Tissue Analysis using MALDI MS/MS  
MALDI-TOF MS has proven to be a valuable discovery tool for the 
identification of disease biomarkers from biological samples, including the 
analysis of proteins directly from tissue sections.[36, 37, 54-57]  The success of direct 
tissue analysis by MALDI-TOF MS can be attributed to the minimal sample 
pretreatment steps and the technique’s high tolerance for tissue impurities (e.g. 
salts).[39]   
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Figure 5.  Schematic representation of the MALDI-QqTOF mass spectrometer.   
Adapted from www.appliedbiosystems.com/Qstar    
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The analysis of tissues by MALDI-TOF MS was further extended to 
preserve the spatial location from which spectra are acquired, and is termed 
imaging MALDI MS.[30, 32, 58] Published results using imaging MALDI-MS/MS for 
the analysis of pharmaceutical compounds in tissue are limited. One of the first 
reports was published by Troendle et al. using a MALDI-QIT-MS to detect the 
drug paclitaxel in a human ovarian tumor sample.[40]  More recently, drug imaging 
of dosed tissue sections was reported by Reyzer et al. using a MALDI-QqTOF 
MS.[38]  The authors initial studies with a MALDI-TOF MS revealed matrix 
interference (m/z 695.2, [3SA+Na]+) with the protonated SCH 226 374 drug 
signal (m/z 695.4) and the peaks could not be differentiated.  Therefore, the 
authors employed the MALDI-QqTOF MS in order to overcome some of the 
limitations from the MALDI-TOF analysis.  The imaging tandem mass 
spectrometry experiment was able to show the unambiguous localization of the 
major CID fragment from SCH 226 374 across a dosed tumor section.  This 
study shows the value and potential of MALDI MS/MS for detecting drug and 
metabolite distributions directly from whole-animal sections, thus providing a 
label-free, molecularly specific imaging technology.  
 
Current Methodologies for Drug Distribution Studies 
Within the last quarter-century, important imaging technologies have been 
innovated for use in the medical field to help make individual patient diagnoses 
and guide therapeutic decisions.[59]  In the past decade, a broader interest has 
been seen in recognizing the value of these technologies for use beyond medical 
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diagnoses.  With better animal models of disease, the ability to image an 
administered drug can help validate potential drug targets, as well as, aid in 
assessing therapeutic efficacy.[60]  For drug distribution studies in whole-animals, 
two approaches can be taken: 1) in vivo imaging or 2) ex vivo imaging.  Both 
approaches require a labeled drug which can be time consuming and costly to 
synthesize.  In addition, the chemical tag may alter the pharmacological 
properties of the compound, which could affect the bioavailability and localization 
of the labeled pharmaceutical within an animal.   The disadvantage of current 
drug imaging technologies is that only the label is monitored, preventing the 
differentiation of a drug from a metabolite that has retained the label. On the 
other hand, these imaging technologies have the ability to interrogate anatomical, 
molecular, or physiological parameters of an animal model, but again, give little 
information as to the molecular identity of many biological end-products that 
result from administration of a drug compound. Early determinations of tissue 
distributions and PK/PD profiles of a novel therapeutic compound play a major 
role in the drug discovery and development process and more sophisticated 
technologies are needed to overcome the apparent limitations of the currently 
available imaging modalities.   
 
Nuclear Imaging 
In vivo imaging, which includes magnetic resonance imaging (MRI), 
computed tomography (CT), positron emission tomography (PET), and single 
photon emission computed tomography (SPECT), is currently being used by 
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many researchers to facilitate the drug discovery and development process.[60-62]  
The noninvasive nature of these nuclear imaging modalities allows for repetitive 
or continuous measurements of the physiological or pharmacological response to 
be performed.  Recently, these imaging technologies have been used to 
measure the early PK profile of a variety of new pharmaceutical compounds in 
small animal models, with the most common techniques being SPECT and PET 
imaging.[60, 63, 64]  PK studies by these in vivo techniques require a radiolabel to 
be incorporated into the drug structure.  The selection of a radiolabel is based on 
the imaging modality employed.   
For example, a gamma- (i.e. SPECT) or positron-emitting (i.e. PET) 
radiolabel must provide enough radiation to escape the animal, while at the same 
time, the energy must not be so high that it cannot be collimated or detected 
efficiently.[63]  A frequently incorporated radiolabel in SPECT imaging of 
pharmaceuticals is 99mTc which decays to its normal ground state with a half-life 
of 6.03 h by emitting an easily detectable gamma ray at 140.5 keV.[63]  Similarly, 
a PET radiolabel, 18F, can be used as an efficient label for fluorinated drugs with 
a half-life of 110 min, emitting two 511 keV photons in opposite directions.[64]  A 
list of common radiolabels used in PET imaging can be seen in Table 1.  PET 
imaging has the potential to provide quantitative information similar to that of ex 
vivo techniques (see following section) in a variety of tissues at a spatial 
resolution of 1-6 mm, while SPECT imaging has a lower spatial resolution of 7-18 
mm and is less applicable for quantitation.[64]  Overall, these techniques can 
provide valuable, noninvasive measurements of the three-dimensional (3D)  
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Table 1.  Common radionuclides used for positron emission tomography (PET). 
Adapted from Fischman et al.[64] 
 
 
 
Radiolabel Half-life (min) 
15O 2.0 
13N 10.0 
11C 20.4 
18F 110 
76Br 972 
124I 6048 
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distribution of a radiolabeled pharmaceutical in vivo. 
 
Whole-body Autoradiography 
The ex vivo imaging technique, known as whole-body autoradiography 
(WBA), has become valuable tool for tissue distribution studies and is a 
mandatory procedure for drug approval by the Food and Drug Administration 
(FDA).[65]  Classically, a lead compound is radiolabeled and administered to an 
animal model, a technique that was first introduced by Ullberg in 1954.[66]  The 
selection of a radiolabel can depend on the timescale of the study, chemical 
structure, and known metabolic pathways of the compound.  Typically, 
radiolabels used for drug administration in animals include 14C and 3H.  After 
administration of the radiolabeled compound, the animal is sacrificed on a time-
scale equivalent to the compound’s known pharmacokinetics, which is often 
obtained by high-performance liquid chromatography tandem mass spectrometry 
(HPLC MS/MS).[67]  Whole-body tissue sections are collected at a thickness of 
20-40 µm and WBA images are collected at a spatial resolution of <50 µm.[68]  In 
the case of PK distribution studies, 8-10 week old male rats are commonly used 
for WBA, where sections are collected in the coronal or sagittal orientation to 
maximize the visualization of multiple organs of interest.[69]  Much information 
about the absorption, distribution, and route of clearance of the radiolabeled 
pharmaceutical can be acquired by WBA with an average turnover time of 5 days 
(Figure 6).  However, the detected signal does not distinguish between the  
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Figure 6.  Example of whole-body autoradiography of coronal rat section bearing Hras5 tumor xenografts. a) 0.25 h, b) 
1 h, and c) 2 h following administration of a single intravenous dose of 14C-ZD6126. [70] 
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original radio-labeled compounds from metabolites that have retained the 
radiolabel and represents a significant limitation of WBA.   
 
Summary and Research Objectives 
Improvements in the preclinical steps of drug discovery and development 
are needed to better identify potentially successful drug candidates, while at the 
same time eliminating inferior drug compounds early in the process.  A key 
component of this process is the ability to gain knowledge about the distribution 
and delivery of a novel therapeutic compound to a target organ or tissue, since 
tissue distributions play an essential role in the PK behavior of a drug.  Of even 
greater interest would be the development of a detection system that allows for 
the correlation between drug tissue distribution and pharmacological or 
toxicological effects. 
This research focuses on the development and application of a new 
methodology for the analysis of exogenous (drug) and endogenous (protein) 
compounds in whole-organ and whole-body animal tissue sections by imaging 
MALDI mass spectrometry (IMS).  Data obtained by this novel methodology shall 
demonstrate the capacity to detect and determine the relative concentrations of 
drug in tissues and more importantly, at the same time, the distribution of various 
metabolites.  Such information about the individual contributions of a drug and its 
metabolites is not easily obtainable by currently available imaging techniques 
such as autoradiography.  In addition, detecting protein changes with both spatial 
and molecular specificity will allow for the correlation of drug tissue distribution 
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and therapeutic response within the same sample.  Identifying specific protein 
patterns that relate to drug efficacy or toxicity would lead to important PD 
assessments of novel therapeutic compounds early in the drug discovery and 
development process. 
 
This work was focused on the following research objectives: 
 
Objective 1:  Develop a reliable, reproducible method for the direct tissue 
analysis of endogenous and exogenous compounds from whole-animal tissue 
sections by imaging MALDI MS. 
 
Objective 2:  Employ the methods developed in Objective 1 to image the 
individual distributions of exogenous drug and subsequent metabolites in whole-
rat sagittal tissue sections.  From these images, determine the relative 
concentrations of the exogenous compound across multiple organs. 
 
Objective 3:  Employ methods developed in Objective 1 to evaluate the 
pharmacodynamic effects of drug administration.  Identify early protein markers 
of drug efficacy. 
 
Development of an MS imaging methodology capable of characterizing 
individual drug and metabolite distributions, as well as protein changes as a 
result of drug administration, in whole animal tissues will advance the ever-
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growing need for rapid evaluations of PK and PD parameters of lead compounds. 
Application of this novel methodology will save the pharmaceutical companies 
valuable time and money.  
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CHAPTER II 
 
 
 
PROTOCOL DEVELOPMENT FOR WHOLE-ANIMAL DIRECT TISSUE 
ANALYSIS 
 
Tissue Preparation Protocols 
The direct analysis of pharmaceuticals from dosed tissue sections by 
imaging MALDI MS/MS has great potential, as was described in Chapter I.  
Extending the application to whole-animal tissues will provide a label-free, 
molecularly specific approach to detect the individual distributions of an 
administered drug and its subsequent metabolites, all of which can be 
determined from a single imaging experiment.  Development of this technology 
will have an enormous impact on the pharmaceutical workflow by providing early 
PK/PD assessments of novel therapeutic candidates in small animal models.  
This chapter outlines the sample preparation, analysis, and image 
processing protocols that were developed throughout the context of this research, 
including practical aspects of animal dosing and sacrifice, tissue sectioning and 
mounting, matrix application, and general strategies for direct analysis of 
endogenous and exogenous compounds from whole-animal tissue sections by 
imaging MALDI MS and MS/MS.  
 
Animal Dosing and Sacrifice 
When designing an MALDI MS/MS imaging experiment to determine the 
disposition of an administered pharmaceutical compound, it is important to select 
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the proper small animal model.  In the early phases of drug discovery and 
development, therapeutic candidates cannot be administered to humans, and 
therefore, predictions about the PK/PD properties have to be made from an in 
vivo animal model.  The two most common species include rats and mice, which 
have different metabolic rates and pathways; hence providing vastly different 
metabolite and distribution information.  In general, rats are used for PK/PD 
studies due to their similarity to human pathways for the adsorption, distribution, 
metabolism, and elimination (ADME) of an administered pharmaceutical.[71]  In 
other cases, mice may be preferred, since many more models of disease are 
available in mice rather than rats. In addition, the imaging MALDI MS/MS 
analysis may require more time for the larger rat than a mouse, depending on the 
experimental parameters and should also be considered (to be discussed in 
ensuing sections).  For these reasons, proper thought must be given to the 
choice of a small animal model. 
Once an animal model has been chosen, the amount of drug to administer 
must be determined.  Generally, there are two levels of dosing, 1) physiological 
or 2) pharmacological.  Their differences are subtle, but have important 
implications for the success of a MALDI MS/MS imaging experiment.  
Physiological dosing (1) refers to the minimal dose required to elicit a physical 
change in the animal that returns a process to normal functioning.  For example, 
this can be a hormone replacement therapy that requires very low doses of 
hormone equivalent to endogenous levels.  Pharmacological dosing (2) refers to 
the amount of drug needed to educe a change in function, typically at a level 
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where therapeutic or toxicological effects can be monitored (i.e. over-dosing), 
including the ADME properties of a therapeutic candidate.  On the whole, 
physiological doses are much lower in amount than pharmacological doses and 
may accumulate in tissues at much lower concentrations.  The lower 
concentration of drug throughout the organs in a whole-body tissue section may 
be difficult to detect by MALDI MS/MS and should be tested on an individual 
compound basis.  Therefore, it is recommended that for drug distribution studies, 
pharmacologically relevant doses should be administered to determine PK and 
ADME profiles (MALDI MS/MS), while physiologically relevant doses should be 
used to determine the appropriate PD profile of a drug through proteomic 
analysis (MALDI MS).   
The route of drug administration also plays a key role in the detected 
PK/PD profile studies by IMS.  There are many ways to administer a drug and 
they can be divided into three main categories: 1) topical, 2) enteral, and 3) 
parenteral.  The most common routes of administration for drug distribution 
studies include the enteral and parenteral routes. The enteral route (2) includes 
oral dosing by pills or liquid (i.e. per orum or p.o.) where the desired effect is 
systemic (non-local).  For small animals, this often requires forced administration 
via an oral gavage, which is an apparatus, much like a feeding tube, that is 
guided down the throat of an animal to deliver a precise liquid dose of drug 
directly into the stomach.  The parenteral route (3) includes intravenous (i.v.) or 
subcutaneous injections where the desired effect is also systemic, but instead, 
the drug is administered by routes other than the digestive tract.   Depending on 
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the route of administration, the same drug can produce different results.  For 
example, some drugs are not significantly absorbed into the bloodstream from 
the gastrointestinal tract and their ADME properties will vary greatly after an 
enteral administration rather than a parenteral administration. Enteral routes are 
generally the most preferred for the treatment of chronic disease in humans, 
because of the ease of administration. However, some drugs can not be used 
enterally because their absorption in the digestive tract is low or unpredictable, 
so parenteral administration is generally used to increase the bioavailability of the 
drug.  Since small animal studies are used to predict a human response, the 
route of drug administration should be carefully chosen to match the ultimate 
route of administration to be used in humans.   
 After successful administration of the pharmaceutical compound, the 
animal must be sacrificed for analysis by IMS.  The time from which an animal 
was dosed to when it is sacrificed will depend on the parameters of the 
experiment.  Generally, the time-points for sacrifice are based on 
pharmacokinetic parameters of the drug determined from earlier in vitro studies.  
In any case, the animal must be properly exsanguinated to avoid ion suppression 
effects in the MALDI ionization process[39], as well as, to avoid artificially 
increased detection of drug in highly vascularized tissues and organs.  In the 
case of whole-body tissue sections, cardiac puncture is the preferred method of 
exsanguination, since the integrity of the animal carcass will be preserved.  
Cardiac puncture is performed by anesthetizing the animal, usually with 
isoflurane, and puncturing the heart with a heparin needle and drawing the blood 
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into the syringe, all while the heart is still beating.  The gauge of the needle is 
usually between 18 to 24, and no longer than one inch.  Successful 
exsanguination will result in approximately 1 cc of blood for mice and 3 cc for rats.  
The removal of all the blood from the animal is what ultimately causes death. 
 Immediately after the animal has been sacrificed, the carcass must be 
frozen to minimize any delocalization or enzymatic degradation of the analytes.[39] 
Care must be taken during the freezing process, to maintain a symmetrical form 
of the carcass.  This can be accomplished by the use of a u-shaped metal frame 
that runs the length of the carcass but is slightly narrower than the width of the 
carcass.  The carcass is placed on its back in the metal frame so the spine is 
straight and its paws pointed upward (Figure 7).  The metal frame is then place in 
a mixture of hexane and dry ice (-60 ºC) to produce a rapid freeze, but not too 
harsh where “shock” such as cracking of the tissue can occur, as is often seen 
with the flash freezing of tissues in liquid nitrogen.  The metal frame holding the 
carcass is submerged for approximately 5 min for mice and 10 min for rats.  The 
frozen carcass is then rinsed with cold distilled water to remove excess hexane, 
patted dry with paper towels, and stored at -80 ºC until the embedding step.     
 
Carcass Embedding 
 The orientation of the carcass during the embedding step is an important 
consideration.  Depending on the parameters of the experiment, the carcass can 
be positioned on the metal sample stage to collect coronal (back to stomach), 
axial (nose to tail), or sagittal (left flank to right flank) whole-body sections (Figure  
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Figure 7.  Images of metal frame used to maintain proper carcass form during freezing process in hexane and dry ice. 
a) u-shaped metal frame, b) bird’s eye view of animal position. 
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8).  For drug distribution studies, the animal is usually positioned for sagittal 
sections, since this orientation maximizes the number of organs represented in a 
single whole-body slice.   
When the orientation of the carcass has been decided, it must be set in 
embedding media to preserve the integrity of the tissue during the cutting 
process.  In WBA studies, it is customary to embed the carcass in 
carboxymethylcellulose or CMC; however, for MALDI MS/MS studies, CMC is not 
practical since it can smear across the tissue during the sectioning process and 
cause significant suppression of the analyte signal (Figure 9).  It was determined 
that the carcass could be embedded in distilled water and still provide the 
necessary support during the sectioning process.   
For appropriate embedding, a metal sample stage is fitted with a frame to 
help form the sample block (i.e. embedded carcass).   The two pieces are placed 
in a -80 ºC freezer for 30 min.  While still in the freezer, a wax platform is placed 
on the sample stage to elevate the carcass in order to provide a margin from the 
metal stage for the blade of the cryomacrocut.  Next, the carcass is positioned in 
the proper orientation on the wax.  A small amount of distilled water is added to 
quickly freeze the wax platform and carcass in place (approximately 5 min).  After 
an adequate anchor has been achieved, the frame is filled with distilled water 
until the carcass is completely covered.  To create a frozen sample block, the 
whole assembly is allowed to freeze at -80 ºC for a minimum of 4 hours. 
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Figure 8.  Diagram of three slicing orientations a) coronal, b) axial, and c) sagittal.  Arrows indicate z direction of 
sectioning. 
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Figure 9.  Use of carboxymethylcellulose (CMC) embedding media suppresses MALDI MS ion signal from tissue.  a) 
protein spectra from control tissue and b) protein spectra from CMC embedded tissue 
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Tissue Sectioning and Mounting 
Sectioning takes place at -20 ºC in a whole-body cryostat, known as a 
cryomacrocut.  However, before whole-body tissue sectioning can be performed, 
the frame must be removed and the sample block must be equilibrated at -20 ºC 
for 1 h to avoid cracking of the ice.  Once equilibrated, the sample block is 
secured onto a translational sledge that moves the sample block underneath a 
stainless-steel blade, cutting from left to right.  The blade assembly is motorized 
and precisely advances the blade into sample block at a designated thickness.  
The process of collecting a whole-body tissue section can be tedious, as 
there are many variables to consider.  At a desired level in the carcass, a piece 
of acetate film tape is placed onto the sample blockface and any air-pockets 
smoothed out.  The tape acts as a support to maintain a flat tissue section, 
otherwise the tissue would curl as it came off the blade.  An acrylic block is used 
by the right hand to gently apply pressure onto the sample block just before it 
passes under the blade, in order to ensure the tissue adheres to the tape.  As the 
tissue comes off the blade, the left hand guides the tape at ~45º angle away from 
the blade to prevent the tape from getting caught and torn.  Outside the 
cryomacrocut, the movement and speed of the sledge is controlled by the 
amount of pressure applied to a lever that is driven by the operator’s leg.  
Altogether, these elements must be performed simultaneously to properly obtain 
a whole-body tissue section.   
The sectioning process and tissue thickness depends on the analysis to 
be performed. For drug distribution imaging by MALDI MS/MS, whole-body tissue 
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sections are collected directly onto acetate film tape at 20 µm thickness.  The 
tissue sections are allowed to freeze dry overnight inside the cryomacrocut 
chamber prior to analysis.  For proteomic analysis by MALDI-TOF MS, whole-
body sections cannot be collected directly onto the acetate film tape.  Tissue 
sections that are collected and analyzed directly on acetate film tape are not 
electrically conductive, and therefore accumulate charge on the tape surface 
during the acceleration of the ions into the TOF analyzer, as described in 
Chapter I.  In general, the charging effect produces poor quality spectra and, 
when the build up of charge is large, analyte signal is lost completely.  To 
compensate for the charging effect, the sectioning process is modified to include 
a piece of rice paper between the sample blockface and acetate film tape.  
Collecting the tissue onto the non-sticky rice paper provides a medium from 
which the tissue can be transferred onto a conductive substrate and, until then, 
the sections are stored at -20 ºC.   The sectioning thickness of the tissue is now 
dependent on the adequate tissue transfer off the rice paper and onto the MALDI 
target plate, as well as, the production of high-quality spectra.  The optimal 
thickness was determined to be 20-30 µm (Figure 10).   
The whole-body tissue sections must be prepared in a manner that 
accommodates the sample introduction system of the MALDI mass spectrometer.  
This process is different for the exogenous small molecule analysis than the 
endogenous proteomic analysis; however, both require the use of MALDI target 
plates.  Each MALDI target plate measures 4 x 4 cm and, accordingly, a sagittal 
mouse section typically requires two plates, while a sagittal rat section requires 
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Figure 10.  Rice paper transfer of whole-body tissue sections at various thicknesses. a) 10 µm, b) 20 µm, and c) 30 
µm.  Arrows indicate areas of poor tissue transfer onto MALDI target plate. 
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four.  For small molecule analysis on the MALDI-QqTOF-MS, the tissue mounting 
procedure is relatively simple and straightforward.  The freeze-dried tape section 
is mounted (tissue side up) directly onto consecutive plates using double-sided 
conductive tape and the excess acetate film tape is trimmed.  The rice paper 
sections are transferred via thaw-mounting and require the tissue to make 
contact with a pre-chilled plate.  The tissue is pulled off the rice paper and onto 
the plate by placing a warm hand on the opposite side of the plate.  This can be 
performed for a single sagittal section simultaneously on multiple plates.  After 
approximately 10 s of warming, the rice paper is pulled away from the plate, 
leaving the tissue behind.   
By and large, the rice paper transfer technique has its limitations of poor 
tissue transfer and inadequate reproducibility and should only be performed 
when absolutely necessary, such as for proteomic analyses on a MALDI-TOF-
MS due to charging effects when tissue is left on tape (Figure 11).  Prior to matrix 
deposition, four fiducials are drawn on each plate (discussed in image 
reconstruction section) and a digital scan is acquired at 1200 dpi.  The plates are 
then separated using a razor blade along the seams between each plate, since 
only one plate can be introduced into the mass spectrometer at a time. 
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Figure 11.  Total ion current images of rat head section analyzed by MALDI-TOF MS.  a) rice paper transfer and b) 
tissue on tape.  Arrows indicate areas of charging (i.e. loss of ion signal). 
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Matrix Deposition 
 
General Considerations 
Once the tissue preparation protocols are complete, the next step towards 
analysis by IMS requires matrix solution to be deposited onto the tissue surface.  
For the analysis of whole-body tissue sections, the selection of matrix conditions 
and optimizing application parameters are extremely vital to obtaining high-
quality mass spectra, since many organs with varying surface properties are 
present in a single sample.  The selection of a matrix/solvent combination can 
greatly influence the effective extraction, co-crystallization, and ionization of 
analytes directly from a tissue section, and must be considered for each analyte 
species.  In addition, the method of matrix application must maintain the spatial 
integrity of the analytes within a tissue sample at a desired image resolution, 
while providing homogeneous coverage so as not to negatively affect the 
accuracy of the MS analysis.  This section provides general guidelines for the 
selection and application of matrix conditions for the successful analysis of 
endogenous and exogenous compounds directly from whole-body tissue 
sections by IMS. 
 
Matrix/Solvent Selection 
 The choice of matrix compound plays an essential role in the MALDI 
ionization process.  The three most commonly used matrix compounds are SA, 
CHCA, and DHB.  Each compound has a preferred mass range for application.  
 43
For example, SA is routinely used in the analysis of proteins and high-molecular 
weight analytes, while CHCA is more commonly used for the analysis of peptides 
and low molecular weight species.  The choice of matrix concentration can also 
affect the eventual crystal coverage and quality of the mass spectra acquired 
directly from a tissue section.  It is known that higher matrix concentrations result 
in higher quality mass spectra by providing increased ion yields and signal 
resolution.[39]  And, lastly, the choice of a solvent can influence the effective 
extraction of the analyte out of the tissue, as well as, proper crystal formation.  
Thus, appropriate solvent conditions may vary depending on the chemical 
properties of the analyte, as well as, the chemical properties of the tissue from 
which the analyte will be analyzed.  
In the case of endogenous protein analysis directly from tissue, SA matrix 
at 25 mg/mL in 50:50 acetonitrile:0.2% trifluoroacetic acid (TFA) in water yields 
the best combination of crystal coverage and signal quality for most tissue types 
tested.[39]  Be as it may, in the case of whole-body tissue sections, many tissues 
with varying surface properties are present and the matrix must simultaneously 
crystallize over all areas of the sample in a homogeneous manner to obtain high-
quality, reproducible spectra.  SA matrix alone does not adequately achieve this 
effective coverage from a single application event, since pockets of uncoated or 
amorphous crystal layers can be observed on various tissues across the whole-
body section.  Therefore, matrix selection was optimized by testing a variety of 
matrix combinations to effectively yield the necessary homogeneous crystal 
coverage on all tissue types.  It was determined that a homogenous crystal layer 
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could be achieved using a combination of SA (20 mg/mL) and DHB (5 mg/mL) in 
50:50 acetonitrile: 0.2% TFA in water while still providing high quality protein 
mass spectra.    
In the case of exogenous small molecule analysis, the selection of a 
matrix/solvent combination is of even greater importance, since ionization yields 
are more dramatically affected.[72] This is due to the chemical formula and the 
structure of a drug compound, which are the two important factors that determine 
its chemical properties.  At this time, a universal matrix/solvent combination is not 
available, and therefore combinations should be tested and selected for sufficient 
co-crystallization of the analyte of interest, effective desorption/ionization in the 
MALDI process, and any possible interfering isobaric matrix peaks.  Streamlining 
the selection of a proper matrix/solvent combination for the analysis of 
pharmaceutical compounds directly from dosed tissue will be discussed in more 
detail in Chapter III.  As a rule for whole-body analysis, the matrix/solvent 
combination that is optimal for most tissues and organs should be selected, since 
many different tissue types are present in an entire animal section.  Also, an 
internal standard that is a structural analog to the analyte compound of interest 
should be incorporated into the matrix/solvent combination (~2 µM spike) for 
normalization reasons. 
 
Matrix Application 
 When a proper matrix/solvent combination has been determined for the 
analysis at hand, the matrix must then be deposited onto the tissue surface.  
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Generally, there are two approaches for matrix application, 1) spotting or 2) 
spray-coating, and either approach can be performed manually or robotically.  
The spotting technique (1) involves the dispensing of discrete droplets of matrix 
onto a tissue section.  For imaging studies, this is routinely performed by a piezo 
ink-jet or nozzle-less acoustic-wave robotic spotting system.  Both robotic 
systems allow for the precise ejection of picoliter volume droplets of matrix at 
high resolutions (~150-300 µm).  This process requires several iterations of 
droplet ejection (7-15 passes), which can be very time consuming and, as a 
result, usually reserved for small tissue samples.  For the global analysis of an 
analyte species, such as the proteome, spotted tissue samples generally 
produce highly-reproducible, signal-rich mass spectra. 
The spray-coating technique (2) involves covering the entire sample with a 
homogeneous layer of matrix crystals.  This can be achieved by manually (glass 
reagent nebulizer) or robotically (piezo spray-head) by nebulizing a solution of 
matrix to create a mist of droplets that land on the tissue surface and dry 
independently.  Again, several iterations of spray passes (~30) are required to 
adequately produce an even crystal layer, with a 1-2 min ambient drying time 
between each pass.  Crystal coverage is evaluated by visual inspection using a 
microscope.  The goal of a spray-coating approach is to maximize analyte 
extraction from the tissue, while minimizing analyte delocalization.  Therefore, 
care must be taken to sufficiently wet the tissue with matrix solution, but not to 
saturate the tissue to cause the movement of analytes across the tissue surface.  
Highly reproducible spray-coated spectra can be acquired in global analyses, but 
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by comparison to spotted spectra, are generally of lower-quality since fewer 
peaks are observed in the mass spectra (Figure 12).     
An additional factor to consider, when deciding on a matrix application 
approach, is the spatial resolution of the imaging MALDI MS analysis.  The 
resolution of a spotted tissue will be limited by the matrix spot itself.  Depending 
on the tissue properties, solvent conditions, and the number of ejection passes, 
automatic spots can be reproducibly produced as small as 140 µm in diameter. 
The resolution of a spray-coated tissue is limited by the laser diameter of the 
MALDI source.  Most commercial MALDI MS systems have lasers that can be 
reliably focused down to a 50 µm diameter, before any significant analyte 
sensitivity is lost.   
Also, the average crystal size produced by spray-coating can vary based 
on the matrix/solvent conditions, but are generally around 20-35 µm in size.   
Consequently, the spray-coating approach allows for images to be acquired at a 
much higher spatial resolution than would be possible by spotting.  A recent 
publication was reported where the laser diameter limitation was by-passed using 
a technique known as “over-sampling.”[73]  This technique steps the laser at 
dimensions smaller than the diameter of the beam, but requires that the matrix at 
each pixel be completely ablated, since the laser ablation areas are overlapped. 
In this approach, the image resolution is no longer limited by the laser, but by the 
crystal size instead.   
In the case of whole-body tissue sections, the spray-coating approach is 
preferred since a larger sample area can be adequately coated with matrix in 
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Figure 12.  Comparison of protein spectra acquired from whole-mouse head sections using two different matrix 
application techniques.  a) robotically-spotted brain and b) spray-coated brain. 
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much less time (~1 h/plate) than it would take to robotically spot the sample (> 8 
h/plate).  Time is an important consideration for whole-body tissue analysis, since 
one sagittal section can span multiple plates, all of which need to be analyzed in 
a timely manner to maximize reproducibility.  In addition, the spray-coating 
approach can produce high-quality spectra for the analysis of exogenous small 
molecule analytes (i.e. pharmaceutical compound) since the matrix/solvent 
selection and application are specifically optimized for that analyte alone. 
 
Whole-body Drug Analysis by MALDI MS/MS 
 This research is focused on developing a reliable method to image 
endogenous and exogenous compounds in whole-animal tissue section by 
MALDI MS.  Previous work has shown that imaging MALDI MS is a sensitive 
sampling technique that can detect over 500 individual protein signals from a 
single tissue section, and that these signals collectively represent a snapshot of 
the proteome.[32, 34]  Comparing the protein signal patterns between large sets of 
samples can help identify key proteins directly or indirectly involved in disease 
progression, prognosis, and drug efficacy or toxicity.[36, 37, 55-57, 74, 75] It has also 
been shown that MALDI MS/MS can be used to monitor the spatial localization of 
drug within a dosed tissue section.[33, 38] A major advantage of drug imaging by 
MALDI MS/MS is molecular specificity. In other words, MALDI MS/MS is capable 
of differentiating an intact drug from metabolites that differ in mass.  As a result, 
imaging whole-body tissue sections by MALDI MS/MS can be useful for the 
label-free visualization of drug and metabolite distribution.  This technology will 
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allow for earlier analysis of therapeutic candidates in the drug discovery process 
since no additional synthesis of a chemically or radio-labeled drug is required. 
 The optimization protocols necessary for developing a whole-animal 
proteome analysis occur in the sample preparation and the image reconstruction 
stages.  The image acquisition and data processing protocols have remained the 
same as previously established imaging MALDI MS methods, detail about which 
can be referenced elsewhere.[34, 76]  Therefore, this section will focus on the 
optimization of acquisition parameters necessary for the analysis of exogenous 
compounds from whole-body tissue sections by MALDI MS/MS. 
 
General Considerations 
The analysis of small molecules by MALDI-TOF MS/MS has limitations, 
most notably spectral noise from the matrix, matrix clusters, and fragment ions 
that occur in the same molecular weight range of most drug compounds (< 1000 
Da).[77]  Moreover, the matrix is present in excess (5000:1) over the analyte of 
interest, overwhelming the low mass region of the spectrum. The problem 
becomes even more complex when directly analyzing tissue because there is a 
relatively high concentration of salt (Na+ and K+) on the tissue surface.  The salt 
acts as an anchor around which multiple matrix molecules can cluster.  For 
protein analysis, the tissue can be washed with ethanol rinses to remove excess 
salts; however, this is not recommended for exogenous small molecule analysis, 
since the drug can leach out of the tissue and into the wash solution.  Another 
interference can be contributed by endogenous small molecule species that can 
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be co-crystallized and desorbed along with the analyte of interest.  Therefore, it is 
important when optimizing the MALDI MS/MS instrument parameters that these 
interferences be considered, especially when selecting a window for mass 
filtering of the precursor ion.  It is also recommended that appropriate controls 
are performed to ensure interfering signals do not share an isobaric signal that 
could be misinterpreted as drug signal.       
It is imperative to take into account the time needed for the analysis of 
multiple plates from a single whole-body tissue section.  The image resolution, 
signal accumulation time, and the number of signal transitions monitored all 
contribute to the total analysis time, and then must be multiplied by the number of 
plates in queue for analysis.  For example, two transitions at 4 s accumulation 
time each that are monitored across a whole-rat sagittal section (4 plates) at 400 
x 400 µm resolution will take a total of 96 h or 4 days to acquire.  Therefore, 
experimental time constraints should be considered when optimizing the 
instrument parameters. Lastly, it is vital to maintain the instrument at an equal 
performance level for all plate analyses.  The monitoring of an internal standard 
transition is recommended for each plate analysis.  This will allow for evaluation 
of the instrument performance and normalization of artificial spectral variations 
that may occur during the analysis.  Collectively, all of these considerations will 
minimize the plate-to-plate variations that can occur during a whole-animal 
imaging experiment.  
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Instrument Parameter Optimization 
 Optimizing the spectrum quality of a dosed tissue requires tuning the 
instrument settings to maximize the drug signal that can be detected.  Ideally, the 
instrument parameters should be optimized for each analyte (drug and 
metabolites) of interest in order to achieve the best signal sensitivity.  The key 
parameters include the mass filter window, collision energy, CID pressure, and 
TOF mass range.  The MS/MS parameters are generally optimized using drug 
and metabolite standards.  To maximize sensitivity, wide mass windows centered 
on the analyte of interest are allowed to pass into the collision chamber (± 2.5 
Da).  Typical collision energies are between 25 to 40 eV with a CID pressure of 
0.03-0.04 mTorr.  Argon or air can be used as the CID gas.  A small mass range 
(~100 Da window) centered on the major CID fragment peak is selected in order 
to maximize the pulsing rate of the orthogonal TOF.  In addition, the number of 
seconds accumulated per transition is optimized for sensitivity and total analysis 
time.  Signal accumulation time is generally 4 s/transition.  
 
Data Processing 
 Two major factors are taken into account when processing data from a 
whole-body analysis: 1) ionization efficiency, and 2) extraction efficiency of the 
analytes.  Ionization efficiency (1) includes considerations for the specific 
ionization yield of an analyte in the MALDI process.  For example, tissue specific 
ion suppression can occur, as well as, disparity in the amounts or properties of 
matrix crystals across different tissues can produce artificial variations in the 
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detectable analyte signal.  To correct for these erroneous analyte signals, an 
internal standard (IS) is incorporated into the matrix application step.  The IS is a 
structural analog of the drug and metabolites of interest and is added within the 
concentration range of analyte signals (typically 1-4 µM).  Since the IS 
concentration should be equal across the whole-body section, the detected IS 
signal can be used to normalize any tissue specific ion suppression or uneven 
matrix coating effects that may occur in the imaging experiment (Figure 13).   
Signal suppression in the MALDI process is compound specific, as well as, tissue 
specific and should be tested for each analyte.  If the drug and metabolite signals 
behave similarly, then a single IS can be employed.  Figure 14 demonstrates the 
signal suppression that can occur for a drug, olanzapine (OLZ), and its 
metabolites, N-desmethyl- and 2-hydroxymethyl olanzapine, across brain, liver, 
and kidney tissues.  In this case, 2 pmol of each compound standard was 
deposited onto the surface of the tissue using an ink-jet printer and allowed to dry.  
At the same coordinates, a matrix solution containing an IS spike was deposited.  
Analysis of the spots by MALDI MS/MS revealed signal variations for each of the 
compounds; however, normalizing against the IS signal corrected for the 
ionization yields within each tissue type.  Variation in total ionization yields of 
compounds from different tissue types is an issue that cannot be corrected by the 
addition of an IS alone. 
Extraction efficiency (2) considers the affinity of a compound for a tissue 
type, as well as, the effective extraction of that compound out of the tissue by the 
matrix solvent.  Since many tissues are coated with matrix simultaneously, a 
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Figure 13.  Internal standard normalizes MALDI MS/MS ion image.  a) raw signal and b) normalized signal. 
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Figure 14.  Histogram of tissue specific ion suppression effects of 2 pmol compound on tissue. a) raw signal and b) 
internal standard normalized signal.  
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single solvent system must be used and may not be optimal for all tissue types 
present in a whole-body section.  For this reason, only a fraction of the analyte 
may be extracted out of a tissue during the matrix application step, and the 
subsequent image would only indicate a low level of analyte to be present in that 
tissue.  If quantitative information is to be extracted from the MALDI MS/MS 
images, then signal intensity alone could misrepresent the actual concentration 
of drug present in the tissue and a normalization factor should be considered 
before interpreting the image data.  For example, Figure 15 demonstrates the 
extraction efficiencies of OLZ and its metabolites through brain, liver, and kidney 
tissue sections (detailed protocol explained in Chapter III).  The concentration 
curves show a linear response for each compound; however, their extraction 
efficiencies across each tissue are different, with the exception of the N-
desmethyl olanzapine metabolite.  This approach allowed for extraction 
normalization factors to be determined, which were then applied to the image 
signals to calculate the relative quantities of drug across a whole-body tissue 
section (Chapter IV).  A similar approach can be taken to determine the 
extraction efficiencies of any pharmaceutical compound of interest and 
application of the extraction normalization factors will afford quantitative 
information to be concluded from the MALDI MS/MS imaging results. 
 
Whole-Body Image Reconstruction 
A whole-body analysis produces a very large dataset that must be 
managed effectively to extract any useful information.  Imaging software provided  
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Figure 15.  Extraction efficiencies of drug compounds through brain, liver, and kidney tissues.  a) olanzapine standard 
curves, b) N-desmethyl metabolite standard curves, and c) 2-hydroxymethyl metabolite standard curves. 
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by the instrument manufacturer can display the imaging results adequately; 
however, in the case of whole-body analysis, results span multiple plates and 
must be combined.  For this purpose, custom software was developed to 
assemble the individual images for reconstruction of a whole-body image (Figure 
16). 
 During the tissue mounting step, four fiducials were placed in the corner of 
each MALDI plate of the sample.  An optical image (1200 dpi jpeg) of the intact 
whole-body section was acquired and then the plates were separated for 
individual analysis.  Before each image acquisition, the motor coordinates of the 
four fiducials are recorded.  After data acquisition of all plates is complete, the 
MALDI MS/MS images are reconstructed using the manufacturer’s software.  In 
this software, the IS signal ( ISS ) can be selected for normalization of the analyte 
signal ( aS ):   
    100
1
⋅+= IS
a
normalized S
S
S  
Since the same concentration of IS was used for each matrix application, 
and the same volume of matrix was applied to each plate, the intensity threshold 
is set to the same value for each imaging experiment.  The resulting MALDI 
MS/MS image is saved as a jpeg file and this process is repeated for each plate.  
Using the custom software, each of the MALDI MS/MS jpegs are loaded into the 
program along with the motor coordinates from the instrument.  In addition, the 
jpeg pixel coordinates for each of the fiducials from the optical image of the intact 
whole-body section is loaded.  The custom software performs a calculation to  
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Figure 16.  Custom software developed for reconstruction of a whole-body MALDI MS/MS ion image. 
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determine the mathematical factor necessary to match the motor coordinates to 
the jpeg pixel coordinates of the fiducials.  The imported MALDI MS/MS jpegs 
are then sized accordingly and assembled to reconstruct the whole-body image 
(Figure 17). 
 
Summary and Conclusions 
 Successful application of a MALDI MS based imaging methodology for the 
detection of exogenous small molecules from whole-body tissue sections can 
provide unique information on the individual drug and metabolite distributions, as 
well as, endogenous protein changes as a result of drug administration.  The 
methods discussed here were effectively applied to the analysis of drug, 
metabolite, and protein compounds in whole-animal tissue sections.  This MALDI 
MS imaging methodology has great potential and the tissue preparation, matrix 
deposition, analysis, and data processing protocols outlined in this chapter can 
serve as a guide for future applications. 
 
Materials and Methods 
 The MALDI matrices, sinapinic acid (SA) and 2,5-dihydroxybenzoic acid 
(DHB), were purchased from Sigma Chemical Co. (St. Louis, MO).  HPLC grade 
acetonitrile, ethanol, hexane, isopropanol, and methanol were purchased from 
Fisher Scientific (Suwanee, GA).  Trifluoroacetic acid (TFA) was purchased from 
Burdick and Jackson (Muskegon, MI).  Acetate film tape and conductive double-
sided tape were purchased from 3M Laboratories (St. Paul, MN). 
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 Tissue sections were cut on a Leica CM3600 cryomacrocut (Leica 
Microsystems Inc., Germany).  Endogenous protein images were acquired on 
either an Autoflex II MALDI-TOF-MS (Bruker Daltonics Inc., Billerica, MA) 
equipped with a 200 Hz Smartbeam laser or a Voyager DE STR MALDI-TOF-MS 
equipped with a 337 nm nitrogen laser operating at 20 Hz.  Data were obtained in 
positive, linear mode with an accelerating voltage of 20 kV, under optimized 
delayed extraction conditions (200-300 ns).  Imaging MALDI-MS/MS analyses 
were performed on QStar XL oMALDI-QqTOF-MS (Applied Biosystems Inc., 
Foster City, CA) equipped with a 337 nm nitrogen laser operating at 20 Hz.  
MS/MS data were obtained in positive mode, with a collision energy of 25 eV with 
an argon collision gas at a CID pressure of .04 mTorr.  Unless otherwise noted, 
images were acquired at 600 x 400 µm lateral resolution with each pixel 
representing the signal sum of 4 s/transition. 
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CHAPTER III 
 
 
 
PREDICITING MATRIX CONDITIONS FOR THE ANALYSIS OF EXOGENOUS 
COMPOUNDS IN TISSUE BY MALDI MS/MS 
 
Introduction 
 It has been previously reported that sample preparation procedures are 
key for the reproducible detection and analysis of analytes directly from tissue 
sections by MALDI MS based technologies.[39, 78]  This becomes even more 
critical for the analysis of exogenous small molecules, such as drug compounds, 
by MALDI MS/MS.  Evidence has been shown that average MALDI MS/MS 
signal intensity of small molecules is dependent upon matrix choice and tissue 
type.[35, 78, 79] Currently, there are no established trends known for matrix/solvent 
preferences of small molecules in dosed tissue, and therefore, time consuming 
optimization procedures are needed before a MALDI MS/MS imaging study of 
dosed tissue can commence.   
In this chapter, the development of a dosed tissue model assay for the 
high-throughput screening of potential exogenous small molecules for analysis 
by MALDI MS/MS and their preferences for matrix/solvent combinations will be 
discussed.  By identifying drug class trends for matrix/solvent preferences, 
sample preparation of dosed tissues will have a guideline for analysis by MALDI 
MS/MS saving both time and resources.   
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Results 
 After many attempts of perfecting the model, a successful assay workflow 
was established and is comprised of five key steps: 1) image acquisition of a 
fiducial marked plate, 2) robotic printing of a 2 pmol drug standard array, 3) thaw-
mounting of two 20 µm thick overlaid tissue sections over the drug array, 4) 
robotic printing of matrix/solvent combinations, and 5) analysis on the MALDI-
QqTOF-MS (Figure 18).  Each plate was prepared with only one drug compound 
and three tissue types, brain, liver, and kidney.  The three most commonly used 
MALDI matrices, sinapinic acid (SA), α-cyano-4-hydroxycinnamic acid (CHCA), 
and 2,5-dihydroxybenzoic acid (DHB) were tested in this study.  Each matrix was 
prepared in either 50% or 75% acetonitrile or methanol for a total of 12 
matrix/solvent combinations (Table 2).   
To validate the matrix/solvent preferences predicted by the model, a 
similar workflow was employed for the analysis of dosed tissue sections, except 
that no drug standard was spotted onto the plate prior to tissue mounting.  
Comparisons of the model assay results to the actual matrix/solvent preferences 
observed from dosed olanzapine and spiperone tissues demonstrates good 
correlation (Figure 19-21).  MALDI MS/MS analysis of dosed brain, liver, and 
kidney tissue from rat revealed an overall preference for DHB as compared to SA 
and CHCA for detected drug signal.  A similar preference for DHB from drug 
standards extracted through control liver sections was observed (model).  
Therefore, any trends observed by the dosed tissue model should predict for the 
actual matrix/solvent preference of a drug from dosed tissue. 
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Table 2.  List of matrices and solvents mixed to make matrix/solvent combinations. 
  
Matrices Solvent Compositions 
sinapinic acid (SA) 50:50 acetonitrile:water (I) 
α-cyano-4-hydroxycinnamic acid (CHCA) 75:25 acetonitrile:water (II) 
2,5-dihydroxybenzoic acid (DHB) 50:50 methanol:water (III) 
  75:25 methanol:water (IV)  
 
 
 
 
 
 
 
 
 66
 
 
 
 
 
Figure 19.  Comparison of the model assay response to the response from dosed brain shows good correlation. 
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Figure 20.  Comparison of the model assay response to the response from dosed liver shows good correlation. 
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Figure 21.  Comparison of the model assay response to the response from dosed kidney shows good correlation. 
 
 
 
a 
b Spiperone Dosed Kidney vs. Model
I II III IV I II III IV I II III IV
CHCA SA DHB
Matrix/Solvent Combination
N
or
m
al
iz
ed
 A
ve
ra
ge
 In
te
ns
ity
 (A
.U
.)
Dosed
Model
Olanzapine Dosed Kidney vs. Model
I II III IV I II III IV I II III IV
CHCA SA DHB
Matrix/Solvent Combination
N
or
m
al
iz
ed
 A
ve
ra
ge
 In
te
ns
ity
 (A
.U
.)
Dosed
Model
 69
As a result, the model assay was then applied to three compounds within 
three different drug classes (Table 3).  Overall, a minimum of 20 spots were 
analyzed per matrix/solvent combination, producing a total of ~20,000 spectra 
representing the matrix/solvent preferences for all 9 small molecules analyzed 
from the brain, liver, and kidney tissues (Figure 22).  By comparing the overall 
response for all variables in this study, individual class trends could now be 
identified.  For example, the benzoazepine class preferred 50% organic solvent, 
the butyrophenone class 50% methanol, and the isopropylamino-phenopropanol 
class 50% acetonitirile, all with DHB matrix.  The comparison was further broken 
down to identify trends based on tissue type (Figures 23-25).  Generally for all 
compounds, I preferred DHB in 50% organic solvent for brain sections, DHB in 
methanol for liver, and kidney data showed no strong preference for any 
particular matrix/solvent combination tested. 
Standard curves of OLZ and SPN were also printed on the plate to 
compare the extraction efficiencies of the compounds through the different 
tissues using DHB in 50% methanol (Figure 26).  Across the concentration range, 
OLZ had similar extraction efficiencies, while SPN exhibited more dramatic 
differences for each tissue type (Table 4).  SPN was extracted through kidney 
with the highest efficiency followed by liver and brain.  In addition, these curves 
can be used to determine extraction normalization factors needed when 
comparing drug signals between the different tissue types (Chapter IV).   
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Overall Brain Comparison
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Figure 23.  Comparison of the matrix/solvent preferences of three drug classes as determined by the dosed brain 
model assay. 
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Overall Liver Comparison
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Figure 24.  Comparison of the matrix/solvent preferences of three drug classes as determined by the dosed liver 
model assay. 
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Overall Kidney Comparison
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Figure 25.  Comparison of the matrix/solvent preferences of three drug classes as determined by the dosed kidney 
model assay. 
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Figure 26.  Comparison of the extraction efficiencies of OLZ and SPN through the different tissues using the 
matrix/solvent combination of DHB in 50% methanol (DHB III). 
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Table 4.  Comparison of average signal intensity for 2 pmol of OLZ and SPN detected through brain, liver, and kidney 
tissue using the matrix/solvent combination of DHB in 50% methanol (DHB III). 
 
 
Average Signal 
(2 pmol) Brain Liver Kidney Normalization Factor 
OLZ 5683.3 25 %CV 
4291.0 
19 %CV 
4855.8 
39 %CV 
Brain 1.0 
Liver 1.3 
Kidney 1.2 
SPN 23192 33 %CV 
39420 
28 %CV 
49168 
23 %CV 
Brain 2.1 
Liver 1.2 
Kidney 1.0 
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Discussion 
It is believed that the detection of drug compounds from dosed tissue 
relies on solvent preferences for extraction, as well as, the incorporation of the 
extracted drug into the matrix crystals.  It is known that several factors influence 
these preferences and include the molecular structure of the analyte (i.e. 
chemical properties) and permeability of the target tissue, for example.[80-82]  
Collectively, it is reasonable to assume that the simple diffusion of a drug could 
vary significantly between tissues within an animal.  In this study, a model was 
developed that mimics dosed tissue matrix/solvent preferences for drugs across 
three classes, the benzoazepine, butyrophenone, and isopropylamino-
phenopropanol classes.  Drug compounds in the benzoazepine class are 
sedative-hypnotic agents that are commonly used for the treatment of a variety of 
symptoms including seizure control, anxiety, alcohol withdrawal, and insomnia, to 
name a few. Butyrophenones are a class of pharmaceutical drugs used to treat 
various psychiatric disorders such as schizophrenia.  The drug compounds 
representing the isopropylamino-phenopropanol class are β-adrenergic 
antagonists and are used for the treatment of hypertension in cardiac patients. 
The structures and therapeutic targets of each of these drug classes are different 
and it would be reasonable to expect the matrix/solvent preferences to differ 
across these classes. 
The dosed tissue model assay was validated by selecting a compound 
from each class and administering a pharmacologically relevant dose to a rat.  
The rats were sacrificed 2 h post-dose and the brain, liver, and kidney organs 
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were removed.  Analysis of these dosed organs identified the actual 
matrix/solvent preferences that should be mimicked by the model.  Trends for 
matrix/solvent preference predicted by the dosed tissue model assay correlated 
very well to the dosed tissue results, indicating the model does in fact mimic 
dosed tissue preferences.  Subsequent analysis of the 9 compounds using the 
dosed tissue model assay identified trends across the different drug classes and 
tissue types.  It was determined that DHB produced the highest detected signal 
for most compounds analyzed and should be a good general matrix for small 
molecule analysis from dosed tissues.  The choice of solvent was determined to 
be more dependent upon the tissue type chosen for the analysis than the drug 
structure itself.  Therefore, when analyzing a whole-body tissue section 
containing multiple tissue types, it is important to select the solvent that is 
acceptable for most tissue analyzed. 
   To determine the extraction efficiencies of the drugs in this study, a 
dilution series of drug standard was automatically spotted on the MALDI plate 
and overlaid with tissue in the same manner as the model.  A single drug was 
chosen to represent each class and DHB in 50% methanol was selected as the 
“generic” matrix/solvent combination.  From the data collected the extraction 
efficiency of the generic matrix combination in brain, liver, and kidney was 
evaluated and provided a means to calculate normalization factors.  The 
butyrophenone class demonstrated the best extraction efficiency with 71% of the 
drug detected by the assay, while the benzoazepine class reported an extraction 
efficiency of 42%.  Furthermore, the standard curve was used to see if absolute 
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quantities of drug could be determined using the model assay.  Approximately 
0.1 pmol of OLZ drug was detected in the actual dosed liver tissue as determined 
by the extracted standard curve; however, previous HPLC-MS/MS extraction 
studies from liver homogenate indicate that ~0.3 pmol of drug should be present 
within the dosed tissue area analyzed.  Therefore, DHB in 50% methanol 
extracted ~33% of dosed OLZ, while our model demonstrated an approximate 
extraction efficiency of 42% for OLZ.  Thus, while the model does not precisely 
represent the absolute quantities from dosed tissue, it is still capable of 
mimicking the matrix/solvent preferences and can be used to predict optimal 
matrix conditions for direct tissue analysis by MALDI MS/MS without the need for 
expensive animal studies. 
   
Materials and Methods 
 
Materials 
 The MALDI matrices, 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic 
acid, SA), α-cyano-4-hydroxycinnamic acid (CHCA), and 2,5-dihydroxybenzoic 
acid (DHB), were purchased from Sigma Chemical Co. (St. Louis, MO).  HPLC 
grade acetonitrile, methanol, and hexane were purchased from Fisher Scientific 
(Suwanee, GA). HPLC grade cyclohexane was purchased from Acros Organics 
(Geel, Belgium).  Fischer 344 rats were purchased from Charles River 
Laboratory, Inc. (Wilmington, MA).  Standards of clozapine (CLOZ), 
carbamazepine (CARB), spiperone (SPN), haloperidol (HALO), bromperidol 
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(BROM), propranolol (PPL), acebutolol (ACE), and atenolol (ATEN) were 
purchased from Sigma Chemical Co. Zyprexa tablets (OLZ) were obtained from 
the Vanderbilt University Hospital Pharmacy (Nashville, TN).  All animal studies 
were approved by the Institutional Animal Care and Use Committee at Vanderbilt 
University.  
 
Tissue Preparation 
One drug compound from each class was administered (p.o.) at 
pharmacologically relevant doses to 10 week-old male Fischer 344 rats, which 
had fasted overnight prior to start of study.  OLZ drug was administered at 8 
mg/kg, SPN at 5 mg/kg, and PPL at 10 mg/kg.  Animals were euthanized at 2 h 
post-dose by isoflurane anesthesia followed by exsanguination via decapitation.  
Control and dosed brain, liver, and kidney were harvested and frozen in 
powdered dry ice.  All samples were stored at -80 ºC until sectioning.  Control 
organs were reserved for model assay (see next section).  Dosed tissue sections 
of 20 µm thickness were collected at -20 ºC using a Leica CM3050s 
cryomicrotome (Leica Microsystems, Inc., Germany) and thaw-mounted to gold-
coated MALDI target plates.  All plates were stored in a vacuum desiccator for 2 
h prior to matrix deposition.  Each sample was robotically spotted with 40 nL (40 
passes, 10 drops/pass, 100 pL/drop) of each matrix/solvent combination (see 
table 2) using a piezo ejection chemical inkjet printer (ChIP, Shimadzu, Kyoto, 
Japan) for a total of 20 spots per combination. All matrix/solvent combinations 
were prepared fresh at 15 mg/mL and contained an internal standard spike of 2 
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pmol.  All matrix spotted tissue sections were stored in a vacuum dessicator for 
~12 h until MALDI MS/MS analysis.   
 
Model Assay Preparation 
At beginning of each drug analysis, a gold-coated MALDI target plate is 
marked with four fiducials (one in each corner of the plate) and an image is 
acquired on a flat-bed scanner at 600 dpi and saved as a tiff.  The plate is then 
loaded onto the robotic spotter (ChIP, Shimadzu) and a scanned image is 
acquired by the instrument.  The instrument acquired scan is then taught (i.e. co-
registered) to the imported tiff image based on the fiducial markings.  For each 
plate, one drug compound is printed in an array of 38 x 26 spots with 1mm 
spacing (988 spots total).  A 1 mM solution of drug is printed in 2 passes of 10 
drops/pass at 100 pL/drop resulting in 2 pmol of drug standard on plate.  The 
plate is then removed from the spotter and allowed to dry in the dark for 15 min.  
Using a Leica CM3050s cryomicrotome at -20 ºC, two 20 µm thick tissue 
sections of each control brain, liver, or kidney organ are overlaid and thaw-
mounted onto gold-coated MALDI target plate covering the printed drug array.  
All plates were stored in a vacuum desiccator for ~2 h prior to matrix deposition.  
The plate was then returned to the spotter and retaught using the same fiducials 
(realignment error was determined to be <10 µm).  At the exact same 
coordinates as the drug spots, 40 nL (40 passes, 10 drops/pass, 100 pL/drop) of 
each matrix/solvent combination is printed for a total of 20 spots per combination.  
Again, all matrix/solvent combinations were prepared fresh at 15 mg/mL and 
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contained an internal standard spike of 2 pmol.  Matrix spotted tissue sections 
were stored in a vacuum dessicator for ~12 h until MALDI MS/MS analysis.   
 
MALDI MS/MS Analysis 
Analyses were performed on a QStar XL (MDS Sciex, Concord, Canada) 
equipped with an oMALDI source (20 Hz 337 nm nitrogen laser) and a hybrid 
QqTOF mass analyzer to obtain MS/MS data.  Instrument parameters were 
optimized for each compound.  Generally, fragmentation was achieved using a 
collision energy of 25-40 eV with an argon collision gas at a pressure of 0.04 
mTorr.  Each drug was monitored for the CID fragmentation of the parent drug 
into its major fragment (see Figure 21).  Two transitions, analyte and internal 
standard, were monitored per spot with 5 s accumulation time per transition (total 
of 10 s/pixel).  Each array was automatically acquired with intraspot rastering 
pattern using the oMALDI 4.0 software.   
 
Data Processing 
 For the model assay and dosed tissues, the analyte signal intensity was 
normalized against internal standard signal intensity from each matrix/solvent 
spot.  Within each matrix/solvent combination, normalized signals were q-tested 
(95% confidence level) for outliers and then averaged.  Signal averages were 
then normalized to the DHB III signal for graphical representation (excel) of the 
dosed tissue model assay comparisons across all three drug classes and tissues. 
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CHAPTER IV 
 
 
 
DRUG AND METABOLITE IMAGING IN WHOLE ANIMAL SAGITTAL TISSUE 
SECTIONS USING MALDI MS/MS 
 
Introduction 
 Modern pharmaceutical research has been greatly influenced by the 
advent of new technologies, such as genomics, proteomics, combinatorial 
chemistry, and high-throughput screening, each promising to enhance the 
discovery of new therapeutic compounds.  This has led to a large number of 
hypothetical targets with exponentially more potential drug candidates.  It was 
hoped that these technologies would give rise to more “promising” lead 
candidates.  However, the increased number of potential drug candidates and 
high-throughput screening assays has not yet resulted in a commensurate 
increase in research productivity. Of the few lead compounds that have 
advanced onto the development phase, even fewer (if any) can be credited to the 
new drug discovery paradigm.[83]  The attrition rates of these development 
compounds can be attributed to poor analytical pharmacokinetic (PK) 
assessments of the potential lead candidate in the discovery phase.  Most of the 
discovery phase PK studies are in vitro assays, or computer-based in vivo 
prediction models that are necessary to evaluate the countless drug candidates 
produced from combinatorial libraries.[11, 16, 17, 71]  Despite their speed and 
throughput, these systems are poor predictors of in vivo PK response.  Therefore, 
the main reason drugs fail in the development phase is unacceptable PK 
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parameters.  The success of pharmaceutical research will now depend on new 
analytical technologies that can detect where a drug candidate and its 
metabolites are distributed in a whole-animal since tissue distribution plays an 
essential role in the PK behavior of a drug.   
 In recent years, the potential of IMS based imaging technologies has 
become apparent for the quick, label-free, and molecularly specific analysis of 
drugs directly from tissue sections.[38, 40, 84]  Development and application of IMS 
for the imaging of whole-animal tissue sections can help assess the potential 
value of a lead candidate earlier in the drug discovery process.  These early PK 
evaluations will improve the quality of lead candidates that enter the development 
phase, before expensive man-hours and resources are wasted. 
 In the study presented here, efforts were focused on the development and 
application of a novel imaging MALDI MS/MS methodology that can analyze 
exogenous compounds directly from whole-animal tissue sections, while at the 
same time, providing quantitative information about the relative distribution of that 
compound across the various organs.  Rats dosed with pharmacologically 
equivalent amounts of olanzapine (OLZ) were chosen since previous data using 
quantitative whole-body autoradiography (WBA) were available as reference[85] 
for the MALDI MS/MS method development.   
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Results 
 
Whole-Rat Olanzapine and Metabolite Imaging 
 In the case study of olanzapine and its metabolites, MALDI MS/MS 
analysis was performed to monitor the major fragment from the collision induced 
dissociation of the precursor compound (Figure 27).  Standard curves of OLZ 
and metabolite standards were linear over a concentration range of 0.006 to 600 
pg/mL with a correlation coefficient of >0.992.  The lower limit of detection for 
OLZ and metabolite standards spiked on tissue was 1 fg. 
 To ensure that no interfering signal could be misinterpreted as olanzapine 
or metabolite signal, proper control experiments were performed using the same 
instrument parameters that were optimized for the imaging study.  A control (non-
dosed) whole-body sagittal tissue section from rat was imaged, and no interfering 
fragment peaks at m/z 256, 270, or 272 were detected at the transitions 
corresponding to drug, metabolites, or internal standard (Figure 28).  In addition, 
the spectra indicate no matrix interference since a DHB solution was used for the 
analysis of the control tissues.  Therefore, all detected fragment peaks represent 
true drug and metabolite signal. 
After a single 8 mg/kg oral dose of OLZ, drug and metabolites were 
present in measurable amounts in almost all tissues at 2 and 6 h post-dose and 
fewer tissues at 24 h post-dose.  At the 2 h time point, OLZ is observed to be 
ubiquitously distributed throughout the whole rat, with significant localization in 
specific organs (Figure 29).  The highest OLZ signal was detected in the lung  
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Figure 27.  Fragmentation spectra for OLZ, metabolites, and internal standard.  a) Olanzapine m/z 313Æ256, b) 2-
hydroxy-methyl olanzapine metabolite m/z 329Æ272, c) N-desmethyl olanzapine metabolite m/z 299Æ256, and d) 
internal standard m/z 327Æ270.  
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Figure 28.  Example spectra from control liver tissue analysis with DHB contain no interfering endogenous or matrix 
signals.    a) olanzapine transition m/z 313Æ256, b) N-desmethyl transition m/z 299Æ256, c) 2-hydroxymethyl 
transition m/z 329Æ272, and d) internal standard transition m/z 327Æ270.  Arrows pointing at location of expected 
fragment peak. 
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Figure 29.  Comparison of WBA and MALDI MS/MS detection of olanzapine at 2 h post-dose in a whole-rat sagittal 
tissue section.  a)  whole-body autoradiography of [14C] OLZ shows distribution of all labeled compounds[85], b) MALDI 
MS/MS detects individual OLZ and metabolite distribution.   
a 
b 
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followed by the spleen, bladder, kidney, liver, thymus, brain and spinal cord, and 
testis.  This observation is in full agreement with previously published OLZ WBA 
data.[85]   A list of abbreviations can be referenced in Table 5. 
For the first time, metabolite distribution was detected using the whole-
body MALDI MS/MS technology and revealed that the metabolites, N-desmethyl 
and 2-hydroxymethyl olanzapine, collectively contributed 21% of the total MS/MS 
signal.  The N-desmethyl metabolite was detected primarily in the liver, kidney, 
and bladder and contributed 8% of the total MS/MS signal.  The 2-hydroxymethyl 
metabolite was detected with the highest signal in the bladder followed by the 
liver and kidney.  This second metabolite contributed 13% of the total MS/MS 
signal.  It should be noted that little to none of these metabolites was detected in 
the brain and spinal cord.  These data are consistent with previous evidence that 
the metabolites have no central nervous system pharmacological activity.[86] 
At 6 h following OLZ administration, static drug distribution was again 
detected throughout the whole-body section, with OLZ signal greatly decreased 
in the brain and spinal cord regions at 66% less ion signal than the 2 h time point 
(Figure 30).  This observation correlated to previous studies that found a 78% 
decrease in [14C]OLZ concentration from 2 to 6 h in brain tissue.[85]  The 
decrease in detected OLZ signal indicated clearance of the drug from the target 
organ.  OLZ was detected at the highest amount in lung, followed by localization 
in liver, bladder, testis, and thymus.  Metabolite distribution remained unchanged, 
with localization primarily in lung, liver, and bladder.  The combined metabolite 
signal was 28% of the total MS/MS signal, with individual contributions of 13%  
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Table 5.  List of tissue abbreviations. 
 
Abbreviation Tissue 
Bl blood 
BM bone marrow 
Br brain 
CC cecum contents 
Ep epididymis 
Ey eye 
Fe feces 
HG Harderian gland 
IC 
intestinal 
contents 
Ki kidney 
Li liver 
LN lymph node 
Lu lung 
My myocardium 
Pa pancreas 
PG pituitary gland 
PrG prostate gland 
SC 
stomach 
contents 
SG salivary gland 
Sk skin 
SM smooth muscle 
Sp spleen 
Te testis 
TG thyroid gland 
Th thymus 
UB urinary bladder 
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Figure 30.  Comparison of WBA and MALDI MS/MS detection of olanzapine at 6 h post-dose in a whole-rat sagittal 
tissue section.  a)  whole-body autoradiography of [14C] OLZ shows distribution of all labeled compounds[85], b) MALDI 
MS/MS detects individual OLZ and metabolite distribution.   
a 
b 
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and 15% for the N- desmethyl and 2-hydroxymethyl olanzapine metabolites, 
respectively.  Again, little to no metabolite signal was detected in the brain and 
spinal cord regions.  Interestingly, the 2-hydroxymethyl metabolite was detected 
in the testis at 6 h post-dose, although it was not present in the testis at 
detectable levels in the 2 h post-dose section. 
MALDI MS/MS images acquired at 24 h post-dose, indicate the majority of 
the OLZ has eliminated from the rat and is corroborated by the WBA images[85] 
(Figure 31).  Signals were detected at much lower levels and the image 
thresholds were adjusted for visualization (10x for OLZ, and 2x for the 
metabolites).  OLZ was detected in a few organs, with the highest signal in 
Harderian gland, testis, and cecum. Metabolite distribution was confined primarily 
to the cecum and kidney.  It is intriguing to note that no OLZ or metabolite signal 
was detected by MALDI MS/MS or WBA in the cecum at previous time points.  
The combined metabolite signal was 63% of the total MS/MS signal, with 
individual contributions of 47% and 16% for the N-desmethyl and 2-
hydroxymethyl metabolites, respectively. 
 Reproducibility of the MALDI MS/MS image acquisition was assessed by 
comparing the 2 h OLZ signal detected from skeletal muscle tissue, since this 
tissue was represented on each of the four plates spanning a single whole-rat 
sagittal tissue section (Figure 32).  A whole-body sagittal rat image acquired in 
this study contains ~27,000 pixels. A Bartlett’s test for plate-to-plate signal 
variance, as well as, an analysis of variance (ANOVA) test were performed on 
sampled skeletal muscle pixels (~300) from each plate and confirmed no  
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Figure 31.  Comparison of WBA and MALDI MS/MS detection of olanzapine at 24 h post-dose in a whole-rat sagittal 
tissue section.  Signals amplified for visualization.  a)  whole-body autoradiography of [14C] OLZ shows distribution of 
all labeled compounds[85], b) MALDI MS/MS detects individual OLZ and metabolite distribution.   
 
a 
b 
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Figure 32.  Plot of the average OLZ MALDI MS/MS signal from skeletal muscle across four sample plates 
demonstrates the reproducibility of the imaging methodology. 
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significant differences, indicating a highly reproducible whole-body image can be 
acquired using the methodology described here. 
 
Olanzapine Quantitation by HPLC-MS/MS 
 For validation of the OLZ signal intensity variations observed across 
different tissues in a whole-rat MALDI MS/MS image, quantitation by traditional 
HPLC-MS/MS methods were employed.  OLZ was extracted from dosed organ 
homogenates to determine the bulk concentration of drug in brain, liver, and 
kidney (Table 6).  The ratios of the HPLC-MS/MS values were compared to the 
ratios of the normalized OLZ MALDI MS/MS signal from the tissue brain, liver, 
and kidney regions (Table 7).  At all time points, imaging signal ratios correlated 
very well to the extraction study.  Similar results were obtained for the metabolite 
MALDI MS/MS image signals; however at the request of Eli Lilly and Co., that 
data cannot be shown.  Nevertheless, quantitation results indicate that the 
MALDI MS/MS imaging methodology can be used to detect the relative amount 
of drug in tissues across a whole-body section tissue. 
 
Discussion 
Olanzapine (brand name Zyprexa) is a drug of the thienobenzodiazepine 
class and is generally used to treat mood disorders such as schizophrenia and 
acute mania in bipolar patients.  As with many atypical antipsychotic drugs, the 
precise mechanism of action for OLZ is unknown.  However, it has been 
proposed that OLZ works by blocking certain serotonin type 2 (5HT2) and  
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Table 6.  Bulk quantitation results of OLZ from tissue extracts. 
 
  HPLC-MS/MS Quantitation (µg/g) 
OLZ 2 h 6 h 24 h 
Brain 57.3 ± 18.7 3.74 ± 1.43 2.64 ± 0.78 
Liver 91.5 ± 21.3 30.2 ± 6.15 29.7 ± 5.94 
Kidney 117.0 ± 4.81 52.9 ± 4.45 13.7 ± 2.47 
 
 
 
 
Table 7.  Comparison of OLZ tissue ratios from MALDI MS/MS imaging signals to HPLC-MS/MS quantitation 
 
. 
 MALDI MS/MS Imaging HPLC-MS/MS Quantitation
OLZ 2 h 6 h 24 h 2 h 6 h 24 h 
Liver/Brain 1.59 ± 0.75 
11.2 ± 
3.77 N/A 
1.60 ± 
0.44 
8.07 ± 
2.37 
11.3 ± 
2.82 
Kidney/Liver 1.29 ± 0.50 N/A 
0.49 ± 
0.26 
1.28 ± 
0.18 
1.75 ± 
0.25 
0.46 ± 
0.09 
Kidney/Brain 2.06 ± 0.86 N/A N/A 
2.04 ± 
0.38 
14.1 ± 
3.31 
5.18 ± 
1.24 
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dopamine receptors.[86]  Pharmacokinetic studies of OLZ indicate that it is well 
absorbed after a single-dose oral administration, reaching peak plasma 
concentration within 5-8 h in humans[86] and within 45 min for rats.[87]  At 2 h post-
dose, WBA data revealed that radioactivity associated with [14C]OLZ was readily 
distributed throughout the tissue of an entire rat[85]; however, no information as to 
the molecular identity of the drug was obtainable by this technique.  The MALDI 
MS/MS images obtained in this study are the first examples of simultaneous drug 
and metabolite imaging in whole animals, thus allowing for the systemwide 
evaluation of each compound in a single animal section. 
Biochemically, three families of cytochrome P450, CYP1, CYP2, and 
CYP3, are known to participate in the metabolism of drugs.[88]  Previous studies 
suggest that OLZ is eliminated extensively by first-pass metabolism, acting as a 
substrate for the cytochrome P4501A2 and P4502D1-5 enzymes in rat 
(analogous to human CYP1A2 and CYP2D6), with 40% of the OLZ dose 
metabolized before reaching systemic circulation.[86]  Olanzapine’s tmax for peak 
concentration in rat tissues was determined in previous PK studies to be 2 h 
postdose.[85, 89]  In the 2 h MALDI MS/MS images, the drug is clearly localized in 
the target organs brain and spinal cord.  The prominent signal for OLZ in the liver 
is consistent with significant drug elimination by first-pass metabolism.  However, 
OLZ was also seen localized to the bladder, indicating elimination in an 
unchanged form, consistent with previous drug data which found that 7% of the 
OLZ dose was recovered in the urine in its original form.[86] 
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The study also shows that liver, kidney, and bladder had prominent 
signals for OLZ and its metabolites, N-desmethyl and 2-hydroxymethyl 
metabolite.  On the basis of the MALDI MS/MS images, the 2-hydroxymethyl 
metabolite, produced by the CYP2D1-5 enzymes, was detected as the more 
abundant metabolite over the N-desmethyl olanzapine.  This may be due to 
several factors: 1) five isoforms of the CYP2D enzymes exit in rat[88] (as apposed 
to the single form present in human, CYP2D6) allowing for increased substrate 
(OLZ) uptake and metabolite (2-hydroxymethyl olanzapine) turnover; 2) 
differences in the relative expression and catalytic activity of CYPs in rat liver 
versus human liver can result in large variations in the in vivo metabolic 
clearance of OLZ; and 3) external sources of variability such as diet, exercise, 
and environmental exposure can modulate activity of the CYP2D enzymes.  It 
has been determined that at steady-state conditions (multiple dosing) in human 
the 10-N-glucuronide and N-desmethyl metabolites are the major circulating 
metabolites produced by direct glucuronidation and CYP1A2 pathways, 
respectively.[86]  In the case of rat metabolism, little is known about the 
involvement and preference of CYPs after a single oral dose of OLZ; however, 
the formation of glucuronide metabolites is an insignificant pathway for metabolic 
clearance of drugs[90], and these metabolites were not detected in this study.  
Additional studies will be needed to identify all major metabolic pathways and 
enzymes responsible for the clearance of OLZ in rats.  
Since the traditional means of quantifying a drug from tissue requires 
excision of the tissue or organ, homogenization and extraction, and analysis on a 
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LC-triple quadrupole system, these same classical procedures were performed in 
this study.  The comparison of the imaging MALDI MS/MS OLZ signal in the 
target organ, brain, and other major organs (liver and kidney) to the HPLC 
MS/MS quantitation study of dosed tissue homogenates showed good correlation. 
However, an analysis by MALDI MS/MS gains the advantage of preserving the 
spatial distribution of the analyte within a tissue sample.   The strong correlation 
of relative drug quantities validates the dynamic signal intensities detected by 
MALDI MS/MS in a whole-animal tissue section.  In addition, this study 
demonstrates the reproducibility of the MALDI MS/MS imaging methodology, 
since consistent signals were accurately obtained from the individual analysis of 
multiple plates over several days.   
In this study, MALDI MS/MS was successfully applied to whole-rat sagittal 
sections.  Individual distributions of olanzapine and its subsequent metabolites 
were monitored across an entire rat in a label-free and molecularly specific 
manner by the novel imaging MALDI MS/MS methodology.  In addition, the 
MALDI MS/MS images accurately represented the relative quantities of OLZ 
present in tissues across the whole-rat section. 
 
Materials and Methods 
 
Materials 
 The MALDI matrix, 2,5-dihydroxybenzoic acid (DHB), was purchased from 
Sigma Chemical Co. (St. Louis, MO).  Olanzapine (OLZ) drug and metabolite 
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standards were produced by Lilly Research Laboratories (Eli Lilly and Co., 
Indianapolis, IN). HPLC grade acetonitrile, methanol, and hexane were 
purchased from Fisher Scientific (Suwanee, GA).  HPLC grade cyclohexane was 
purchased from Acros Organics (Geel, Belgium).  Fischer 344 rats were 
purchased from Charles River Laboratory, Inc. (Wilmington, MA).  For animal 
dosing, Zyprexa tablets (OLZ) were obtained from the Vanderbilt University 
Hospital Pharmacy.  All animal studies were approved by the Institutional Animal 
Care and Use Committee at Vanderbilt University.  
 
Tissue Preparation 
 OLZ drug was administered at pharmacologically relevant doses (p.o. 8 
mg/kg) to 10 week-old male Fischer 344 rats, which had fasted overnight prior to 
start of study.  Animals were euthanized at 2, 6, and 24 h post OLZ dose by 
isoflurane anesthesia followed by exsanguinations via cardiac puncture.  Control 
and dosed animal carcasses were frozen in hexane/dry ice and stored at -80 ºC.  
Individual animal carcasses were frozen in a block of ice, and 20 µm thick whole-
body sagittal tissue sections were collected on acetate film tape (3M, St. Paul, 
MN) using a Leica CM3600 cryomacrocut (Leica Microsystems, Inc., Germany) 
at -20 ºC.  Tissue sections were allowed to freeze-dry overnight at -20 ºC.  
Whole-body tissue sections were then mounted onto consecutive gold-coated 
MALDI target plates (Applied Biosystems, Inc., Foster City, CA) using conductive 
double-sided tape (3M).  All plates were stored in a vacuum desiccator until 
analyzed.  Each plate from a single 20 µm thick dosed whole-body tissue section 
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were individually spray-coated with 20 mL of DHB (40 mg/mL) in 70% methanol, 
2 µM 2-ethyl olanzapine internal standard spike, using a glass spray nebulizer 
(Kontes, Vineland, NJ).  At 30 cm from the target plate, a cycle (3 spray passes) 
of matrix coatings was applied for 25-30 cycles, with 1-3 min ambient drying time 
between cycles.  All matrix coated tissue sections were allowed to dry under 
ambient conditions for ~1 h prior to MALDI MS/MS analysis.   
    
MALDI MS/MS Imaging 
Image analyses were performed on a QStar XL (MDS Sciex, Concord, 
Canada) equipped with an oMALDI source (20 Hz 337 nm nitrogen laser) and a 
hybrid QqTOF mass analyzer to obtain MS/MS data.  Fragmentation was 
achieved using a collision energy of 30 eV with an argon collision gas at a 
pressure of 0.04 mTorr.  OLZ and metabolite detection was performed following 
the transitions:  1) OLZ m/z 313Æ256, 2) N-desmethyl olanzapine m/z 299Æ256, 
3) 2-hydroxymethyl olanzapine m/z 329Æ272, and 4) internal standard m/z 
327Æ270.  Two transitions, analyte and internal standard, were monitored per 
pixel with 4 s accumulation time per transition (total of 8 s/pixel).  Each image 
was automatically acquired at 600 x 400 µm lateral resolution with a pixel shift of 
200 µm for each subsequent analyte image.   
 
Data Processing  
 After completion of the MALDI MS/MS image acquisition, each plate was 
individually processed using the oMALDI server 5.0 software.  Images were 
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normalized against internal standard signal and total signal threshold was set for 
each analyte image:  1) OLZ = 65, 2) N-desmethyl olanzapine = 9, and 3) 2-
hydroxymethyl olanzapine = 9.  Images were saved as jpeg files and imported 
into custom reconstruction software (Chapter II) to produce a single whole-body 
analyte image.  Reconstruction error was found to be <48 µm (less than one 
MALDI MS/MS image pixel and 2 jpeg pixels).   
For the OLZ image signal quantitation study, regions of interest were 
extracted from the MALDI MS/MS images using the oMALDI server 5.0 software.  
Average signal intensity and standard deviation for the image region were 
recorded.  Extraction normalization factors (Chapter II) were applied to the 
average signal from each region:  1) brain = 1.0, 2) kidney = 2.0, and 3) liver = 
1.4.  Ratios of the normalized OLZ signal averages from each organ were then 
compared to the ratios of the bulk HPLC-MS/MS quantitation values extracted 
from tissue homogenates.        
 
Drug and Metabolite Quantitation  
 Extraction study was modeled after published protocols of OLZ 
quantitation from dosed tissues.[87, 89, 91]  Each excised brain, liver, and kidney 
organ (N=3 per organ) was weighed and mass recorded.  Organs were sampled 
in triplicate, and for each 100 mg of tissue, 1 mL of deionized water and 3 µg of 
internal standard was added and the mixture was homogenized (15 mL glass 
homogenizer, Fisher Scientific) until the homogenate appeared uniform by visual 
inspection.  Homogenate was transferred to a 20 mL borosilicate glass test tube 
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(Fisher Scientific).  Homogenizer was rinsed 2 times with 1 mL deionized water 
and rinse was added to test tube.  A 1:1 volume of 0.5 M NaOH was added to the 
test tube and vortexed.  A 10 mL volume of cyclohexane extraction solvent was 
added, test tubes capped, and inverted at 4 ºC for 2 h.  After inversion, the test 
tubes were centrifuged for 20 min.  Organic layer was then transferred to a new 
test tube to dry under nitrogen gas at 37 ºC.  Samples were reconstituted in 300 
µL of 10 mM ammonium acetate in 50% acetonitrile.  Standard curves were 
prepared by spiking a control homogenate with the OLZ standard, which covered 
a concentration range of 1-1000 ng/g. 
 Samples were randomized and analyzed in triplicate on an ESI TSQ 
Quantum triple-quadrupole system (Thermo Scientific, Waltham, MA) equipped 
with an autosampler (set at 4 ºC) and HPLC system.  A C12 Synergi MAX-RP 
150 x 2 mm column (Phenomenex, Torrance, CA) was used with a fast gradient 
run of mobile phase A (5:95 acetonitrile:0.5% acetic acid in water, 10 mM 
ammonium acetate) to mobile phase B (95:5 acetonitrile:0.5% acetic acid in 
water, 10 mM ammonium acetate). 
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CHAPTER V 
 
 
 
IMAGING MALDI MASS SPECTROMETRY FOR THE DISCOVERY OF 
MOLECULAR FEATURES INDICATIVE OF EARLY DRUG EFFICACY 
 
Introduction 
Essential to the success and approval of a drug by the FDA, 
pharmacodynamic (PD) studies are required to evaluate the pharmacological 
response of a therapeutic candidate.  PD studies usually occur in the 
development stage using small animal models to determine mechanisms of 
action, as well as, acceptable parameters of a compound before advancing on 
into the clinical trials.[11]  These parameters include establishing therapeutic 
efficacy, dosing schedule, and potential toxicity of an administered compound.[11, 
13, 80, 92]  Several mechanisms can be responsible for the observed 
pharmacological effects of a compound and are often unpredictable by in vitro 
studies performed in the discovery phase.  For this reason, animal studies are an 
invaluable tool to help assess the PD profile of a drug in vivo. 
Evaluation of a drug’s PD profile is traditionally based on the phenotypic 
response of an animal.  These responses can be determined from behavioral 
studies, diagnostic imaging, or detection of a biochemical endpoint.[71, 80]  The 
latter has become a major driving force for the evaluation of pharmacological 
response due to the recent discovery of many biomarkers.  These biomarkers 
are obtained by extensive genomic and proteomic studies and can be selected to 
represent a desired biological endpoint.[3, 61, 93]  Unfortunately, biomarkers are not 
 105
available for the evaluation of all therapeutic pathways, since the in vivo 
mechanisms of action for most new drug compounds are not completely 
understood.  As a result, evaluations based on phenotypic responses such as a 
decrease in tumor burden determined by an imaging study or physiological 
improvements observed by a behavioral study are heavily relied upon.   
In addition, these biochemical or physiological changes are related to the 
PK profile of the drug.[11, 14, 64, 80]  In other words, the concentration-effect 
relationship is used to provide a comprehensive picture of the activity of a drug, 
perhaps uncovering its mechanism of action. Drug concentrations are typically 
determined from plasma samples; however, with a few exceptions, most drugs 
exert their pharmacological activity in a target tissue and not the plasma.  
Furthermore, protein binding of drugs in the plasma can influence the rate of 
uptake into tissues, while at the same time, a drug’s binding affinity to a target 
can also influence the amount of drug localized in a particular tissue.[80]  
Therefore, kinetically, the rate of drug diffusion into tissue and the amount of drug 
sustained in tissue are independent processes.  Often times, this relationship is 
not equal and plasma drug concentrations alone do not accurately represent the 
extent of drug in tissues, further complicating any conclusions that can be drawn 
from the PK/PD studies.  Correlating the spatial distribution of a drug in a target 
tissue with an observed pharmacological response is an essential component to 
understanding the PK/PD profile of a drug and still remains a difficult task to 
accomplish.[80]  
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Imaging MALDI mass spectrometry has the potential to be used for the 
simultaneous detection of drug distribution and subsequent proteome changes 
from a single tissue sample. Previous work has shown that MALDI-TOF MS can 
be a valuable discovery tool for the identification of disease biomarkers by 
analyzing the proteome directly from a tissue section.[37, 55, 57, 94]  MALDI-TOF MS 
analyses of proteome effects following drug administration have also been 
reported in the literature.[37, 95]  MALDI MS analyses have capacity to identify 
surrogate biomarkers indicative of pharmacological endpoints long before a 
phenotypic response manifests and can be used to rapidly evaluate the 
therapeutic efficacy or toxicity of a candidate compound.  In addition, the 
previous chapter demonstrated the power of MALDI MS/MS analyses for the 
detection of exogenous drug distribution across multiple tissues present in an 
entire whole-rat sagittal tissue section.   
Consequently, MALDI MS based imaging technologies were used in this 
study to detect the distribution of exogenous lithium and the subsequent 
pharmacological response in the proteome of mice with and without exposure to 
radiation.   This case study was chosen since previous work has uncovered 
radiation as a known cause of neurocognitive impairments in the brain of children 
and adults[96, 97], while recent work has demonstrated that chronic lithium 
administration can have a neuroprotective effect against such injuries.[98, 99]   In 
vivo evaluation of lithium efficacy has been performed by behavioral studies of 
animals that require a minimum 6 week waiting period for a phenotypic response 
to manifest.   To augment this “wait and see” approach, imaging MALDI MS was 
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used to identify molecular features within the detected proteome that are 
indicative of early lithium efficacy against radiation-induced damage.  
 
Results 
 
Experimental Design 
In this study, MALDI-TOF MS was used to directly analyze the proteins 
from radiation exposed mice brains with and without chronic lithium treatment to 
identify molecular features in the mass spectra indicative of early lithium efficacy.  
The experimental design required separating the stock of mice into two groups, 
control and those dosed for eight days with 40 mg/mL lithium.  On day eight, 
immediately following the final lithium dose, the two groups were further 
separated, with one half of each group receiving a single 7 Gy dose of radiation.  
This experimental design ultimately provided four treatment groups: 1) control, 2) 
lithium only (Li+/IR-), 3) radiation only (Li-/IR+), and 4) lithium plus radiation 
(Li+/IR+) mice (Figure 33).  At 1 h post lithium/radiation dose, the mice were 
sacrificed for the imaging LDI and MALDI MS analyses.  For both LDI and MALDI 
MS analyses, three serial sections of whole-mouse head were collected from 
individual animals onto MALDI target plates, as well as, a single serial section 
onto a microscope slide for cresyl violet staining.  The sections reserved for 
MALDI MS analysis were spotted with a high-resolution array of SA matrix 
droplets at 150 µm lateral resolution (Figure 34), while the LDI tissue sections 
required no further sample preparation.  All tissues were analyzed on a MALDI- 
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Figure 33.  Schematic representation of the experimental design, which provided four treatment groups: 1) control, 2) 
lithium only (Li+/IR-), 3) radiation only (Li-/IR+), and 4) lithium plus radiation (Li+/IR+) mice. 
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Figure 34.  Optical images displaying the high-density array of SA matrix droplets at 150 µm lateral resolution on 
mouse brain tissue for analysis by MALDI MS. Right panel is a zoomed-in region of the left panel outlined in red. 
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TOF mass spectrometer under optimized conditions. 
From previous studies, it is known that radiation induced neurocognitive 
effects are a result of injury to the proliferating neuronal progenitor cells in the 
subgranular zone of the hippocampus.[98, 100]  It has also been shown that chronic 
lithium treatment can exhibit a protective effect against radiation.[98, 99]  However, 
for this reason, data only from the hippocampal region was used for the 
discovery of molecular features indicative of early lithium efficacy. In order to 
identify the spectra representing only the hippocampus region of interest, the 
MALDI MS section and its corresponding cresyl violet stained serial section were 
co-registered after image acquisition to extract the data for statistical analysis 
(Figure 35).  Typically, 100-150 spectra were extracted and contained between 
250 to 400 individual protein signals in the mass range of 2-100 kDa.  Evaluation 
of the degree of intra- and inter-sample variability was determined to be ~7 and 
14 % CV, respectively (Figure 36).  Therefore, for a peak (i.e. feature) to be 
considered statistically significant, a >3σ fold change of 50% must be satisfied for 
features meeting a 99.9% confidence level.  Significant features across all 
treatment groups were ranked according to a correlation matrix calculated by 
Kendall's algorithm and paired t-tests were performed for all treatment groups.  
 
LDI MS Imaging of Lithium Distribution in Mouse Brain 
To determine the distribution of lithium in the brain, laser 
desorption/ionization (LDI) mass spectrometry was employed (i.e. matrix-free 
MALDI MS).  Images were acquired at 150 µm lateral resolution with each pixel  
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Figure 36.  Evaluation of spectral variability in the cortex region of mouse brain.  a) example peaks representing intra-sample 
variability of ~7% CV (average of 10 pixels) and b) inter-sample variability of ~14 % CV (3 animals). 
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representing the sum of 100 laser shots.  The 1 h distribution of lithium was 
determined to be ubiquitous throughout all the dosed mice brains (Li+/IR- and 
Li+/IR+) analyzed, with noticeable localization in the gray matter, as well as, the 
hippocampus (Figure 37).  LDI experiments of the non-lithium administered 
brains (control and Li-/IR+) detected no endogenous lithium to be present. 
 
MALDI MS Imaging of Proteome in Mouse Brain 
Preliminary work focused on verifying whether MALDI MS analysis of 
dosed tissues could monitor the temporal increase or decrease of protein signals 
as a result of lithium administration.  Direct analysis of lithium dosed brain tissue 
sections at 15, 30, and 60 min post-dose revealed the largest pharmacological 
response at the 60 min time point (Figure 38).  Since, pharmacological response 
is related to drug concentration, the 1 h time point was selected for the study 
presented here. 
MALDI MS analysis was performed on over 24 individual brain sections, 
producing over 2500 spectra representing the hippocampus proteome of all four 
treatment groups.  Spectra were separated into classes based on treatment 
group for statistical analysis, which revealed over 303 features to be statistically 
significant across the mass range of 2-30 kDa (Figure 39).  Pairwise 
comparisons were performed to identify the subset of features that best indicated 
lithium efficacy (i.e. Li+/IR+ features most like control and least like Li-/IR+).  The 
following comparisons were made: control vs. radiation only, control vs. lithium 
plus radiation, and radiation only vs. lithium plus radiation (Table 8). Of the 
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Figure 37.  Lithium distribution as detected by imaging LDI-MS.  a) optical image of 12 µm whole-mouse head section, 
b) overlay of optical and ion images, and c) LDI-MS ion image of lithium (m/z 7).  Hippocampus region outlined in 
yellow dashed-line. 
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Figure 38.  Temporal lithium dose response in proteome of hippocampus region detected by imaging MALDI MS.  Two 
example features of a temporal increase and decrease as a result of lithium administration are shown in the zoom 
plots.   
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Figure 39.  Overlay of average spectra from each treatment group and examples of statistically significant features 
across the mass range are displayed in the zoom plots. 
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features shared in common between control and lithium plus radiation samples 
(239 features), 30 features were found to be statistically significant from radiation 
only samples. This represents 13% of the total features.  Additionally, only 2% of 
the features (5 out of 303) shared no commonality between control, lithium plus 
radiation, and radiation only samples.  Therefore, 85% of the features are in 
common across the three treatment groups.  It can be concluded that the 30 
features detected by MALDI MS analysis are in fact true differences between the 
treatment groups and not a systematic analytical error.  A list of the 30 features 
can be seen in Table 9 and these features can be considered as early indicators 
of lithium efficacy.    
The average signal intensities of the significant molecular features were 
plotted for comparison across the treatment groups (Figure 40).  Based on the 
plot, lithium treatment can be seen to reduce the effects of altered protein 
expression as a result of radiation exposure when compared to mice exposed to 
radiation without the lithium treatment.  The average Li+/IR+ signal was found to 
be statistically indistinguishable from control. 
The contributions of lithium administration and radiation exposure on the 
detected lithium plus radiation (Li+/IR+) protein signals were evaluated. Pairwise 
comparisons of the features measured as statistically significant between control 
and Li+/IR+ samples were performed against the lithium only and radiation only 
samples (Table 10). Of the 64 features found to be different between control and 
Li+/IR+ groups, 34 features were statistically indistinguishable between the 
lithium only and radiation only groups.  Therefore, it was determined that 9 
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Table 8.  Results of the pairwise comparisons for the statistically significant features. 
 
 
Analysis No. of Features in Common Total Features Percentage of Features 
Control vs. Li-/IR+ 206 303 68% 
Control vs. Li+/IR+ 239 303 79% 
Li-/IR+ vs. Li+/IR+ 240 303 79% 
Control and Li+/IR+ vs. Li-
/IR+ 204 239 85% 
Control vs. Li+/IR+ vs. Li-
/IR+ 204 303 67% 
 No. of Significant Features   
Control and Li+/IR+ vs. Li-
/IR+ 30 239 13% 
Control vs. Li+/IR+ vs. Li-
/IR+ 5 303 2% 
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Table 9.  List of 30 statistically significant features indicative of lithium efficacy. 
 
 
m/z Fold-Change Up / Down t calculated p value (t test) 
p value 
(Wilcoxon) 
3360 1.82 Down 11.04 <0.000001 0 
3437 1.51 Down 9.42 <0.000001 0 
3653 1.76 Down 12.16 <0.000001 0 
3856 2.26 Down 17.51 <0.000001 0 
3865 2.01 Down 15.09 <0.000001 0 
4542 2.27 Down 15.91 <0.000001 0 
4570 1.51 Down 9.77 <0.000001 <0.000001 
4668 2.08 Down 14.09 <0.000001 0 
4989 2.25 Down 19.70 <0.000001 0 
6726 2.52 Down 12.09 <0.000001 0 
7623 2.03 Up 22.03 <0.000001 <0.000001 
7671 2.14 Up 14.51 <0.000001 <0.000001 
7706 2.11 Up 12.21 <0.000001 <0.000001 
7721 2.05 Up 14.24 <0.000001 <0.000001 
7800 1.87 Up 29.2 <0.000001 <0.000001 
7816 1.64 Up 13.37 <0.000001 <0.000001 
7838 1.62 Up 14.24 <0.000001 <0.000001 
8424 2.38 Up 30.46 <0.000001 <0.000001 
8485 1.60 Up 14.04 <0.000001 <0.000001 
8631 1.51 Up 11.65 <0.000001 <0.000001 
9301 2.19 Down 11.35 <0.000001 0 
11070 1.59 Down 11.57 <0.000001 <0.000001 
11385 1.52 Up 5.70 <0.000001 0.0000165 
12412 1.58 Up 15.80 <0.000001 <0.000001 
12436 1.64 Up 18.46 <0.000001 <0.000001 
15332 1.86 Up 6.87 <0.000001 <0.000001 
15617 2.34 Up 7.68 <0.000001 <0.000001 
16793 1.85 Up 16.20 <0.000001 <0.000001 
17046 1.51 Up 9.46 <0.000001 <0.000001 
27803 1.87 Up 15.72 <0.000001 <0.000001 
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Figure 40.  Protein signal plots of the average signal intensity of two features indicative of lithium efficacy show 
reduced aberrant protein expression as a result of radiation exposure.  a) m/z 7800 and b) m/z 16793.   
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features were induced by the lithium administration, while 17 features were 
contributed by the radiation exposure, representing 14% and 27% of the features, 
respectively.  Only four features were unable to be attributed to either lithium 
administration or radiation exposure. 
 
Discussion 
Radiation is a common therapy used for the treatment of both primary and 
metastatic tumors in humans.  In the case of brain tumors, cranial radiation 
treatment causes neurocognitive defects in both children and adults.[96, 97]  
Evidence suggests that neurocognitive defects from cranial radiation may involve 
injury to proliferating neuronal progenitor cells, as well as, radiation-induced 
apoptosis.[101-104]  Lithium has anti-apoptotic activity and has been previously 
shown to have neuroprotective effects against a variety of neurological 
injuries.[105, 106] Specifically, recent studies have shown that chronic 
administration of lithium prior to cranial radiation protects against neurological 
injuries. [98, 99]  Typically, evaluation of lithium efficacy in in vivo radiation studies 
requires a 6 week waiting period for the phenotypic responses of neurological 
injury to manifest.[98]  In this study, imaging mass spectrometry was used to 
monitor the brain proteome of mice exposed to cranial radiation with and without 
chronic lithium treatment to determine potential markers of early lithium efficacy. 
LDI MS imaging analysis of the mice brains following chronic lithium 
treatment for 8 days revealed lithium distribution to be relatively ubiquitous with a 
noticeable accumulation in hippocampus region of interest.  A time course LDI 
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Table 10.  Results of the pairwise comparisons for the features found to be statistically different from control to 
determine the contribution of lithium or radiation for that difference. 
 
Li+/IR+ Features Significant from 
Control  
No. of Features in 
Common Total Features 
Percentage of 
Features 
Lithium induced peaks 
(Li+/IR+ vs. Li+/IR-) 9 64 14% 
Radiation induced peaks 
(Li+/IR+ vs. Li-/IR+) 17 64 27% 
Either lithium or radiation induced 
(Li+/IR- vs. Li-/IR+) 34 64 53% 
 No. of Significant Features   
Neither lithium or radiation induced 
(Li+/IR- vs. Li-/IR+) 4 64 6% 
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MS imaging experiment (data not shown) detected lithium distribution to have the 
highest relative abundance at the 1 h time point.  A similar analysis of the 
hippocampus proteome by MALDI MS analysis revealed a temporal increase in 
pharmacological response, with the largest change in signal detected at the 1 h 
time point.  As a result, the increased pharmacological response detected in the 
proteome could be directly correlated to the increased concentration of lithium in 
the highly localized hippocampus region of the mice brains.  This finding 
demonstrates the capacity of imaging MALDI MS to simultaneously relate the PK 
distribution profile of a drug to its PD response with high spatial resolution. 
Statistical analysis of the protein spectra obtained from the hippocampus 
region of the brain at 1 h post lithium/radiation dose revealed 30 molecular 
features in the control mice that were conserved in the spectra of the lithium 
protected radiation mice but significantly aberrant in the radiation only mice.  
Therefore, it can be concluded that these features are indicative of early lithium 
efficacy and can be used as markers in future studies to rapidly evaluate the PD 
profile of lithium. 
One of the significant features has been previously identified as 
calmodulin (m/z 16793).  Calmodulin is a calcium-binding protein that is known to 
indirectly regulate many cellular functions by binding a multitude of proteins 
involved in inflammation, metabolism, apoptosis, memory, and nerve-growth, to 
name a few.[107]  Evidence has been reported that chronic treatment of lithium 
can lead to the robust inhibition of Ca2+ influx into the granule cells of the 
brain.[108, 109]  If less Ca2+ is present in these cells, then less calmodulin would be 
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needed.  This physiological response can be seen in the temporal decrease of 
calmodulin signal following chronic lithium administration by imaging MALDI MS.   
On the other hand, reports in the literature have suggested that increased 
Ca2+ levels are seen in mitochondria from brain cells that are undergoing 
apoptosis.[110, 111]  It is believed that this increase in Ca2+ is caused by prolonged 
activation of the mitochondrial permeability transition pores.[112] Interestingly, 
chronic lithium treatment has been shown to inhibit glycogen synthase kinase-3, 
a known pro-apoptotic enzyme, while increasing anti-apoptotic proteins such as 
Bcl-2.[98, 113, 114]  The proteins are known to mediate the Ca2+ levels in 
mitochondria by the activation or inactivation of the mitochondrial permeability 
transition pores.  MALDI MS analysis revealed nearly a 2-fold increase in 
calmodulin levels in the radiation only mice as compared to control and Li+/IR+ 
mice.  Radiation exposure is known to cause DNA damage and subsequent 
apoptosis.[ref] Perhaps the increased expression of calmodulin is a result of the 
activation of endogenous repair mechanisms attempting to chelate the excess 
Ca2+.  Thus, the statistically significant detection of calmodulin as an indicator of 
early lithium efficacy can be thoroughly rationalized.  
In summary, the MALDI MS data obtained in this study were able to 
provide 30 molecular features indicative of lithium efficacy.  Correlating lithium 
distribution to proteome response in the hippocampus by LDI and MALDI MS 
analyses provided a means to directly correlate drug distribution with 
pharmacological response and provided insight into the concentration-effect 
relationship.  Further work needs to be performed to determine the identity of the 
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molecular features in order to rationalize the biological significance of these 
proteins and for validation for use of these features as early markers of lithium 
efficacy in future studies. 
For example, the molecular feature previously identified as calmodulin 
was shown to have significant expression levels as result of lithium protection 
against radiation-induced damage in hippocampal cells.  The hippocampus is the 
center for learning and memory and calmodulin has a known role in short- and 
long-term memory.[101]  Now, targeted experiments can be performed to further 
elucidate the exact function of calmodulin in this process.  In addition, imaging 
LDI MS experiments can be performed to monitor the endogenous Ca2+ levels to 
corroborate the detected expression changes of calmodulin in the hippocampus 
region.   
Given that the ultimate goal of PD studies is to relate the pharmacological 
response to dose-concentration or concentration-effect relationships of a 
therapeutic compound and its metabolites, a technology such as imaging MALDI 
MS can provide an invaluable tool to rapidly and reproducibly relate the tissue 
distribution of a drug to the observed pharmacological response within the same 
animal while maintaining spatial resolution.  
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Materials and Methods 
 
Materials 
The MALDI matrix, 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid, 
SA), and lithium chloride salt were purchased from Sigma Chemical Co. (St. 
Louis, MO).  HPLC grade acetonitrile and ethanol were purchased from Fisher 
Scientific (Suwanee, GA). C57BL mice were provided by the department of 
radiation oncology at Vanderbilt University (Nashville, TN).  All animal studies 
were approved by the Institutional Animal Care and Use Committee at Vanderbilt 
University. 
 
Tissue Preparation 
Lithium chloride drug was chronically administered at pharmacologically 
relevant doses (i.p. 40 mg/kg) to 7 day-old C57BL mice for seven days prior to 
start of study.  On day eight, control (non-lithium dosed) and chronic lithium 
administered mice were divided into four treatment groups: control, lithium only 
(Li+/IR-), radiation only (Li-/IR+), and lithium treated radiation exposed (Li+/IR+) 
mice (N=2-3 mice per treatment group).  A final lithium dose was administered 
and immediately following, the radiation mice were given a 7 Gy dose.  All mice 
were euthanized at 1 h post lithium/radiation dose by exsanguination through the 
eye.  Control and dosed carcasses were frozen in hexane/dry ice and stored at -
80 ºC.  Individual animal carcasses were decapitated and the heads sectioned at 
12 µm thickness using a Leica 3050S cryomicrotome (Leica Microsystems, Inc., 
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Bannockburn, IL) at -20 ºC.  Six serial tissue sections from the hippocampus 
region of interest were thaw-mounted onto two gold MALDI target plates (3 
section/plate) and additional serial sections were collected onto microscope 
slides for cresyl violet staining[115].  Tissue sections reserved for LDI and MALDI-
TOF MS analysis were allowed to dry in a vacuum dessicator for ~2 hr prior to 
matrix deposition.  MALDI MS tissue sections were rinsed 2x in 70% ethanol 
wash for 30 s and 1x in 95% ethanol wash for 15 s, then individually spotted with 
25 mg/mL SA prepared in 60:40 acetonitrile:0.6% TFA in water using a Portrait 
630 Reagent Multispotter (Labcyte, Sunnyvale, CA) at 150 µm lateral resolution.  
All matrix coated tissue sections were allowed to dry under ambient conditions 
for ~1 h prior to MALDI MS analysis. 
 
LDI and MALDI MS Imaging 
LDI and MALDI MS image analyses were performed on an Autoflex II 
(Bruker Daltonics, Inc., Billerica, MA) MALDI-TOF mass spectrometer equipped 
with Smartbeam laser technology (200 Hz 355 nm Nd:YAG laser) using the 
FlexImaging 2.0 software (Bruker Daltonics, Inc.).  LDI data were collected at 150 
µm lateral resolution in positive, reflector mode with an accelerating voltage of 19 
kV and a reflector voltage of 20 kV.  LDI spectra represent the mass range of 1-
40 Da and the sum of 100 laser shots per pixel (Smartbeam modulation turned 
off).  MALDI MS data were obtained over the mass range of 2-100 kDa in 
positive, linear mode with an accelerating voltage of 20 kV, and under optimized 
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delayed extraction conditions (300 ns).  A total of 400 laser shots were summed 
over each matrix spot. 
 
Data Processing 
After completion of the LDI and MALDI image acquisitions, data were 
processed for baseline correction (convex-hull), normalized, and ion images 
displayed (peak integration) using the FlexImaging 2.0 software (Bruker 
Daltonics, Inc.).  For the extraction of MALDI MS data, image data sets were co-
registered to cresyl violet stained serial sections using the FlexImaging 2.0 
software.  Pixels corresponding to the hippocampus region, as defined by the 
stained section, were selected and exported for statistical analysis. 
 
Statistical Analysis 
Extracted spectra from the hippocampus region were loaded according to 
treatment groups into ClinProTools 2.0 (Bruker Daltonics, Inc.) statistical analysis 
software.  All spectra were baseline subtracted using a convex-hull algorithm and 
normalized.  Null spectra, as well as, spectra failing to meet a mean signal to 
noise ratio (S/N) of 2.0 across the analyzed mass range were rejected and thus 
not included in the statistical analysis.  Spectra were realigned allowing for a 
possible 1500 ppm mass window shift and a 20% minimum peak-to-peak match.  
Those spectra unable to be realigned by the preceding parameters were withheld 
from data analysis.  The peaks achieving a S/N of 3.0 after all processing steps 
were individually integrated to determine peak area. 
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For statistical analysis, peak areas representing each class were 
averaged and their standard deviations calculated. Pair-wise peak comparisons 
were made between classes.  Deviations were pooled and mean peak areas 
were compared using a t-test, where the calculated t values had to surpass a 
99.9% confidence levels in order to be considered as significant.  Bartlett's test 
was performed to verify the likeness of variance and the inter-animal variability 
was measured to be ~14%.  Therefore, only peaks meeting a 99.9% confidence 
level while exceeding a minimum of 1.5 fold change (>3σ) were deemed to be 
statistically significant.  A correlation matrix was calculated by Kendall's algorithm 
to rank peaks closely associated with those measured as significant. 
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CHAPTER VI 
 
 
 
CONCLUSIONS AND PERSPECTIVES 
 
Endogenous and Exogenous Compound Analysis in Whole-Animal Tissues 
by Imaging MALDI Mass Spectrometry  
 
Through the course of this research, a dosed tissue model assay was 
developed to provide a method for the prediction of matrix/solvent preferences of 
exogenous compounds in dosed tissues for analysis by MALDI MS/MS.  This 
model assay allows for the analysis of any matrix/solvent combination to 
determine the optimal conditions for analyzing exogenous small molecules (i.e. 
drug and metabolite compounds) from dosed tissues.  Additionally, the model 
assay allows for the screening of a large number of drug compounds to 
determine their potential for an imaging MALDI MS/MS experiment without ever 
dosing an animal.     
In summary, the model assay provided a means to streamline sample 
preparation parameters by predicting the optimal matrix/solvent combination for 
analysis of OLZ, as well as other exogenous compounds, in dosed whole-animal 
tissue section by MALDI MS/MS.  Specifically, the model assay identified that 
matrix/solvent conditions were unique to a drug class (i.e. dictated by the 
chemical structure of drug), as well as, the targeted tissue for analysis and that 
DHB in 50% methanol could serve as an adequate universal matrix for first-pass 
qualitative analyses.  This methodology can now be applied to a larger cohort of 
compounds to further identify more significant trends, perhaps in the future, 
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providing a guide for matrix/solvent selection based on the chemical structure of 
the analyte alone. 
Succeeding imaging experiments performed by MALDI MS/MS were able 
to provide the individual, label-free temporal distributions of olanzapine and its 
metabolites in whole-rat sagittal tissue sections with high sensitivity and 
reproducibility.  Image resolution, instrument parameters, and analyte selection 
can be tailored for sensitivity and throughput, further maximizing the 
reproducibility of the imaging MALDI MS/MS application.  Highly-accurate relative 
quantities of olanzapine in brain, liver, and kidney tissues could also be obtained 
from the MALDI MS/MS ion images when proper normalization factors were 
considered.  These results are in line with previous quantitation studies from 
dosed tissue homogenates and WBA distribution studies of olanzapine.[85-87, 89, 90]  
Therefore, it has been demonstrated that MALDI MS/MS imaging can be applied 
in the early PK evaluations of an administered therapeutic candidate and its 
metabolites in a small animal model. 
Moreover, PK studies by MALDI MS/MS can be combined with PD studies 
using MALDI MS.  In the case study presented in Chapter V, proteomic analysis 
by MALDI-TOF MS identified 30 molecular features in the mass spectrum that 
were indicative of early lithium efficacy for protection against radiation-induced 
damage in the hippocampal region of a mouse brain.   The capacity to detect 
drug distribution and proteome response from the same tissue sample will have a 
huge impact on the pharmaceutical industry.  Currently, such correlations are 
performed using unbound plasma concentrations of drug as a surrogate for 
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actual tissue concentrations.  It is believed that pharmacological activity can be 
related to the unbound drug in the plasma.  However, this key assumption is not 
always valid and can make attempts at understanding the relationship between 
drug concentration in target tissues and pharmacological response difficult.   
Therefore, technologies such as MALDI MS based imaging technologies that can 
correlate the actual drug distribution in tissues to pharmacological response in an 
accurate manner will be an essential tool for evaluating the potential success of a 
candidate drug compound.  Establishing and validating the identified biological 
endpoints could provide new biomarkers indicative of efficacy or toxicity. 
Screening for these biomarkers in the proteome by imaging MALDI MS can 
provide a rapid assessment of therapeutic success or whether reoptimization of 
the treatment regimen is needed. 
 
Research Perspectives 
The promise of drug discovery lies in the potential to understand a disease 
process at the molecular level and to determine the optimal molecular targets for 
drug intervention.  Currently, there are only 500 molecular targets for which drugs 
have been developed[116] and it is estimated that there are at least 10 times as 
many molecular targets that can be exploited for future drug therapy than are 
being used today.[1]  Genomics and proteomics offer the promise of providing 
new selective drug targets for a large number of disease, which in turn spurs the 
development of many more therapies aimed at smaller patient populations (i.e. 
individualized medicine).  Validation of the new drug targets will require the in 
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vivo PK and PD evaluations of many new compounds aimed at producing a 
desired therapeutic effect.  Better analytical technologies aimed at answering 
ADME and efficacy or toxicity parameters are needed, while keeping research 
and development expenditures low.   
Imaging mass spectrometry has the potential to improve the 
understanding of complex molecular events that take place at the protein, 
peptide, or lipid level of disease, therapeutic response, or even toxicological 
effects in animal models of disease, while also providing information about the 
individual distribution of drug and metabolites in animal models.  The IMS 
methodology developed in this study for the analysis of endogenous and 
exogenous compounds in whole-animal tissue sections is one significant step 
closer to improving the productivity of pharmaceutical research.   
Much of the IMS methodology can be owed to the established WBA 
protocols, which were expanded upon and optimized for the MALDI MS and 
MS/MS technologies.  Since WBA is a mandatory procedure for drug approval by 
the FDA, integrating whole-body IMS into the pharmaceutical workflow should be 
relatively easy.  However, the true advantage of the IMS technology lies in the 
rapid, label-free and molecularly specific MALDI MS/MS analyses that can be 
performed long before a labeled drug candidate is ever synthesized for WBA.  
Imaging of whole-animal tissue sections by IMS will be a significant means of 
early PK and PD assessments of drug candidates.  These earlier assessments 
will streamline the evaluation and selection of lead compounds entering the 
development phase, where the cost of moving a drug along the pipelines 
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escalates rapidly.  The earlier the PK and PD profiles are established, the more 
tailored drug research can become.  With a more focused understanding of the 
molecular events that lead to a drug candidate’s efficacy or potential side effects 
that can be gained by an IMS analysis, the pharmaceutical industry will have the 
capacity to deliver valuable new therapies to the public, extending and improving 
patients’ lives safely and more effectively. 
 
Future Research Directions 
 This thesis research has developed a methodology to analyze 
endogenous and exogenous compounds directly from whole-animal tissue 
sections; however there are still many questions that need to be explored.  For 
example, the olanzapine study was able to demonstrate the quantitative values 
that can be obtained from a MALDI MS/MS experiment.  Relative information 
about the quantities of drug as it localizes in various tissue in an animal is of 
value; however, the true worth of this technology would be the capacity to detect 
absolute quantities of drug and metabolites across a whole-animal tissue section 
in a single imaging experiment.  Answering this question will not be trivial as 
many factors contribute to the signals observed in an imaging MALDI MS/MS 
analysis.  For example, accumulation of a drug in a particular tissue section is not 
likely to be uniform and therefore a single pixel intensity can not be directly 
correlated to the bulk quantities identified by HPLC-MS/MS. In addition, 
heterogeneous crystal formation and non-uniform inclusion of the analyte into the 
crystals, as well as, shot-to-shot variability of the MALDI process can all 
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contribute to fluctuations in detected drug signal, making absolute quantitation by 
MALDI MS/MS a difficult task. However, it is reasonable to assume that a MADLI 
MS/MS methodology can be developed that will normalize these variations, as 
was the case in this study, which identified the relative quantities of OLZ by 
normalizing the ionization and extraction efficiencies of the analyte in various 
tissues. 
 Imaging MALDI mass spectrometry has also been shown to correlate the 
distribution of a drug to aberrant protein expression or distribution in a tissue 
sample in a qualitative manner.  Of greater interest would be the quantitative 
correlation of protein changes to the absolute drug quantity at a particular 
location in the tissue sample.  This technology could then be readily applied to 
identify potential biomarkers of efficacy or toxicity with high precision and 
accuracy, while possibly providing clues to the mechanism of action seen in the 
pharmacological response.  Furthermore, application of this technique to large 
sample sets can provide an unbiased, high-throughput means of identifying 
molecularly specific features unique to individual non-responders of therapy.  
Identification of these features can aide in the screening of patient populations for 
likely response to a treatment regimen. 
Whole-body imaging has expanded the two-dimensional capabilities that 
have been previously demonstrated by the IMS technology.  Further expanding 
this technology into the z-direction will allow for the three-dimensional analysis of 
whole-animal tissue sections and work has already begun in this area.  Through 
the course of this research, a novel methodology was developed to acquire and 
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reconstruct spatially resolved three-dimensional MALDI MS ion images and to 
co-register these images to in vivo imaging modalities, such as magnetic 
resonance imaging (MRI), CT, and PET.[117]   
A proof-of-concept experiment was performed using a glioma (GL26) 
mouse model to correlate the ex vivo molecular proteomic information gained in 
the MALDI MS analysis to the tissue contrasts observed in the in vivo images 
obtained by MRI.  Prior to the MALDI MS analysis, MR images were obtained on 
a 7T magnet (Varian, Inc., Palo Alto, CA) to produce quantitative parametric 
images of the longitudinal relaxation time (T1), transverse relaxation time (T2), 
and apparent diffusion coefficient (ADC) (Figure 41).  After imaging, the mouse 
was immediately prepared for analysis by MALDI MS (protocol described in 
Chapter II).  During the sectioning process, optical images of each blockface 
section (40 µm) were acquired using a high-resolution digital camera (Canon, 
Inc., Lake Success, NY) and reconstructed into a continuous image volume 
(Figure 42).  Whole-mouse head tissue sections from selected regions of the 
blockface volume encompassing the spatial extent of the tumor were collected 
for analysis by imaging MALDI-TOF MS (150 µm lateral resolution and 300 
shots/pixel).  MALDI MS data were inserted and co-registered to the 
corresponding image slice in the blockface volume. The MRI data was then 
rigidly co-registered to the blockface volume as well, thus inherently co-
registering the MALDI MS to the MRI data.   
For example, ion volumes for two proteins, astrocytic phosphoprotein 
PEA-15 (m/z 15035) and fatty acid binding protein 5 (m/z 15076), were rendered 
 137
 
 
 
 
 
 
a b
c d
 
 
Figure 41.  Co-registered blockface and quantitative MR images obtained on a 7T magnet.  a) coronal blockface 
image of glioma mouse head, b) longitudinal relaxation (T1), c) transverse relaxation (T2), and d) apparent diffusion 
coefficient (ADC).   
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Figure 42.  Reconstructed blockface volume of glioma mouse head.  The mouse head was sectioned coronally in an 
anterior to posterior fashion (units in centimeters). 
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against the corresponding MRI data (Figure 43).  These proteins have been 
previously identified as elevated in grade III gliomas[94], and were detected in the 
tumor region as indicated by the blockface volume and area of tumor contrast in 
the MRI.  These results indicate good correlation between the two imaging 
modalities.  In addition, the 3D MALDI-MS volume was automatically binned 
using a K-means algorithm and the voxels with the highest intensity bin had the 
corresponding T1, T2, and ADC values averaged.  The areas of high protein 
concentration as detected by MALDI MS are in agreement with the contrast 
variations detected in the MRI analysis (Table 11).  This result demonstrates the 
power of relating molecular information gained in the MALDI MS analysis to 
tissue composition contrasts observed in the MRI data.          
The ability to relate proteomic information, both spatially and quantitatively, 
with in vivo imaging data has important implications.  For example, 3D MALDI 
MS analysis can now provide contextual information that can open the door to 
understanding the complex molecular interactions that take place in an animal 
volume.  This approach also enables MALDI MS images to be placed in an 
animal-specific frame of reference, thus permitting the data to be precisely 
interpreted against specific anatomical information.  Moreover, functional 
information from the in vivo studies, such as tumor angiogenesis or tissue 
degradation, can be correlated with proteomic profiles to help elucidate the 
molecular mechanisms of health and disease.  In vivo imaging technologies such 
as CT and PET already have their place in the pharmaceutical workflow, and the 
application of this novel 3D methodology can also be extended to allow for the 
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Figure 43.  Co-registered blockface volume, 3D MALDI MS (yellow), and ADC MR data (gray scale).  a) astrocytic 
phosphoprotein PEA-15 and b) fatty acid binding protein 5 (units in centimeters).  
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Table 11.  Comparison of voxels with high 3D MALDI-MS ion signal and corresponding average T1, T2, and ADC 
parameters from the co-registered MR data.   
 
 
3D MALDI-MS to MRI Correlation T1 (s) T2 (ms) ADC (10-3 mm2/s) 
Tumor 0.85±0.82 33.5±18.2 0.92±0.62 
Injection Insult 1.27±0.46 38.4±11.8 0.97±0.44 
Striatum 0.88±0.70 46.6±7.7 0.92±0.24 
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co-registration of MALDI MS/MS drug distribution data to validate and identify the 
drug target, and any end-points related to the ADME and PK/PD profile of a 
compound. 
 
Conclusions 
In conclusion, a compelling technology has been demonstrated for the 
analysis of endogenous and exogenous in whole-animal tissue sections by 
imaging MALDI MS.  The most challenging aspects of the MALDI based imaging 
technology were the interfacing of a whole-body tissue section to the mass 
spectrometer, and data reconstruction.  Encouragingly, the novel methodology 
developed through this research can now be successfully applied to whole-
animal samples in a robust and reproducible manner.  Such a technology has a 
huge potential to revolutionize the productivity in pharmaceutical research by 
providing a rapid, label-free and molecularly specific ex vivo analysis.  For 
example, applications of this imaging MALDI MS/MS methodology to study the 
temporal distribution of a therapeutic compound and, more importantly, its 
metabolites can provide valuable spatial information which are otherwise missed 
by traditional nuclear imaging techniques or lost in HPLC quantitation studies, 
thus providing a means to determine the ADME and PK profile of an 
administered drug.  Additionally, imaging the resulting proteome effects of drug 
administration by MALDI MS can provide valuable PD profiles that can determine 
a drug’s efficacy or toxicity.  Correspondingly, preliminary work has also 
demonstrated the potential of 3D MALDI to serve as a powerful complement to 
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WBA and PET by providing sample-specific molecular information that can be 
easily implemented into the pharmaceutical workflow.  However, MALDI MS 
based imaging still has its limitations and is not amenable to every drug 
compound or protein of interest, and is an invasive technique.  Nevertheless, the 
powerful analyses that can be performed by MALDI imaging of whole-animal 
sections need to be exploited to know its true value, since there still much to be 
learned from this technology.  It will be exciting to see the impact this technology 
will have on the advancement of pharmaceutical research and our understanding 
of PK and PD properties of drugs at the molecular level. 
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